<units>
<unit type="BATCH">
<unit-content>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="bk"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</author>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
</bibrecord>
<bibrecord> 1st chapter
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_1</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">A Systemic View of Metastatic Disease: Inter-Organ Crosstalk and Therapeutic Implications</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</author>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>As cancer progresses, the communication and crosstalk between cancer cells and the tumor microenvironment become a key determinant of successful cancer cell growth and survival. These interactions arise through either local contact-mediated signaling or the systemic release of soluble factors, extracellular vesicles and particles (EVP) by tumor cells. Systemic effects that are initiated early during cancer progression, when cancer cell growth is still confined to the primary tumor, establish the pre-metastatic niche (PMN). PMN formation lays the groundwork for cancer-cell colonization of distant organs by altering the extracellular matrix, immune-cell composition, and vascular permeability of distant organs. Tumors also independently reprogram host physiology and metabolism, which often results in a debilitating skeletal-muscle-wasting syndrome known as cachexia. Indeed, over 80% of advanced cancer patients develop cachexia and consequently suffer from reduced tolerance to anti-neoplastic therapies and premature death. This introductory chapter summarizes the various systemic effects of cancer that are detrimental to the host. The design of treatments that can prevent and/or reverse these systemic changes is ultimately expected to improve the quality of life and survival of cancer patients.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>6</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="9">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Emergingbiologicalprinciplesofmetastasis.Cell.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2016.11.037</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lambert,A.W.,Pattabiraman,D.R.,Weinberg,R.A.:Emergingbiologicalprinciplesofmetastasis.Cell.168(4),670–691(2017).https://doi.org/10.1016/j.cell.2016.11.037</ref-fulltext> 
<ce:source-text>Lambert,A.W.,Pattabiraman,D.R.,Weinberg,R.A.:Emergingbiologicalprinciplesofmetastasis.Cell.168(4),670–691(2017).https://doi.org/10.1016/j.cell.2016.11.037</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Survivingatadistance:organ-specificmetastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>TrendsCancer.</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.trecan.2015.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Obenauf,A.C.,Massague,J.:Survivingatadistance:organ-specificmetastasis.TrendsCancer.1(1),76–91(2015).https://doi.org/10.1016/j.trecan.2015.07.009</ref-fulltext> 
<ce:source-text>Obenauf,A.C.,Massague,J.:Survivingatadistance:organ-specificmetastasis.TrendsCancer.1(1),76–91(2015).https://doi.org/10.1016/j.trecan.2015.07.009</ce:source-text> </reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Accessoriestothecrime:functionsofcellsrecruitedtothetumormicroenvironment.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>322</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2012.02.022</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hanahan,D.,Coussens,L.M.:Accessoriestothecrime:functionsofcellsrecruitedtothetumormicroenviron-ment.CancerCell.21(3),309–322(2012).https://doi.org/10.1016/j.ccr.2012.02.022</ref-fulltext> 
<ce:source-text>Hanahan,D.,Coussens,L.M.:Accessoriestothecrime:functionsofcellsrecruitedtothetumormicroenviron-ment.CancerCell.21(3),309–322(2012).https://doi.org/10.1016/j.ccr.2012.02.022</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellularvesicle-and particle-mediated communication shapes innate and adaptive immune responses.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Pelissier Vatter</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cioffi</ce:surname>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Hanna</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Castarede</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Caielli</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Pascual</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J.Exp.Med.</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>218</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1084/jem.20202579</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>PelissierVatter,F.A.,Cioffi,M.,Hanna,S.J.,Castarede,I.,Caielli,S.,Pascual,V.,etal.:Extracellularvesicle-and particle-mediated communication shapes innate and adaptive immune responses. J.Exp.Med.218(8)(2021).https://doi.org/10.1084/jem.20202579</ref-fulltext>
<ce:source-text>PelissierVatter,F.A.,Cioffi,M.,Hanna,S.J.,Castarede,I.,Caielli,S.,Pascual,V.,etal.:Extracellularvesicle-and particle-mediated communication shapes innate and adaptive immune responses.J.Exp.Med.218(8)(2021).https://doi.org/10.1084/jem.20202579</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-metastaticniches:organ-specifichomesformetastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="6">
<ce:initials>G..</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc.2017.6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peinado,H.,Zhang,H.,Matei,I.R.,Costa-Silva,B.,Hoshino,A.,Rodrigues,G.,etal.:Pre-metastaticniches:organ-specifichomesformetastases.Nat.Rev.Cancer.17(5),302–317(2017).https://doi.org/10.1038/nrc.2017.6</ref-fulltext> 
<ce:source-text>Peinado,H.,Zhang,H.,Matei,I.R.,Costa-Silva,B.,Hoshino,A.,Rodrigues,G.,etal.:Pre-metastaticniches:organ-specifichomesformetastases.Nat.Rev.Cancer.17(5),302–317(2017).https://doi.org/10.1038/nrc.2017.6</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Primingthe‘soil’forbreastcancermetastasis:thepre-metastaticniche.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
</author>
<author seq="2">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
</author>
<author seq="3">
<ce:initials>E.R.</ce:initials>
<ce:surname>Port</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Dis</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3233/bd-2007-26106</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila,B.,Kaplan,R.N.,Port,E.R.,Lyden,D.:Primingthe‘soil’forbreastcancermetastasis:thepre-metastaticniche.BreastDis.26,65–74(2006).https://doi.org/10.3233/bd-2007-26106</ref-fulltext>
<ce:source-text>Psaila,B.,Kaplan,R.N.,Port,E.R.,Lyden,D.:Primingthe‘soil’forbreastcancermetastasis:thepre-metastaticniche.BreastDis.26,65–74(2006).https://doi.org/10.3233/bd-2007-26106</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Themetastaticniche:adaptingtheforeignsoil.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat.Rev.Cancer.</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc2621</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila,B.,Lyden,D.:Themetastaticniche:adaptingtheforeignsoil.Nat.Rev.Cancer.9(4),285–293(2009).https://doi.org/10.1038/nrc2621</ref-fulltext>
<ce:source-text>Psaila,B.,Lyden,D.:Themetastaticniche:adaptingtheforeignsoil.Nat.Rev.Cancer.9(4),285–293(2009).https://doi.org/10.1038/nrc2621</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Precisiononcologyframeworkforinvesti-gationofexerciseastreatmentforcancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>J.Clin.Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4134</first-page>
<last-page>4137</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.2015.62.7687</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>J
ones,L.W.:Precisiononcologyframeworkforinvesti-gationofexerciseastreatmentforcancer.J.Clin.Oncol.33(35),4134–4137(2015).https://doi.org/10.1200/JCO.2015.62.7687</ref-fulltext>
<ce:source-text>J
ones,L.W.:Precisiononcologyframeworkforinvesti-gationofexerciseastreatmentforcancer.J.Clin.Oncol.33(35),4134–4137(2015).https://doi.org/10.1200/JCO.2015.62.7687</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancercachexia:rationalefortheMENAC(Multimodal-Exercise,NutritionandAnti-inflammatorymedicationforCachexia)trial.BMJ</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Stene</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle></ref-sourcetitle>
<ref-publicationyear first="2018"/>
<ref-text>Support.Palliat.Care</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>258</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1136/bmjspcare-2017-001440</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Solheim,T.S.,Laird,B.J.A.,Balstad,T.R.,Bye,A.,Stene,G.,Baracos,V.,etal.:Cancercachexia:rationalefortheMENAC(Multimodal-Exercise,NutritionandAnti-inflammatorymedicationforCachexia)trial.BMJSupport.Palliat.Care.8(3),258–265(2018).https://doi.org/10.1136/bmjspcare-2017-001440</ref-fulltext>
<ce:source-text>Solheim,T.S.,Laird,B.J.A.,Balstad,T.R.,Bye,A.,Stene,G.,Baracos,V.,etal.:Cancercachexia:rationalefortheMENAC(Multimodal-Exercise,NutritionandAnti-inflammatorymedicationforCachexia)trial.BMJSupport.Palliat.Care.8(3),258–265(2018).https://doi.org/10.1136/bmjspcare-2017-001440</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord> 3rd chap
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_3</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone Metastases: Systemic Regulation and Impact on Host</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Suresh</ce:surname>
<ce:given-name>Sukanya</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</author>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>TX</state>
<country iso-code="USA"/>
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Advanced cancers frequently metastasize to bone and disrupt normal bone remodeling to cause bone destruction. Bone metastases are incurable and result in significant morbidity: Pain, fracture, hypercalcemia, spinal cord compression, and muscle weakness. The associated muscle weakness may occur prior to or in the absence of cachexia. Tumor-induced bone destruction causes the release of growth factors that can fuel tumor progression in bone. These factors can also act systemically to cause muscle weakness. The resulting muscle dysfunction adds to cancer-associated morbidity and can increase the risk of falls and fractures in patients with bone metastases. In this review, we discuss the mechanisms by which bone metastases can induce muscle weakness and potential ways to identify and treat cancer-induced systemic dysfunction.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/book/10.1007/978-3-031-09518-4</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="72">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>CA Cancer J. Clin.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel,R.L.,Miller,K.D.,Jemal,A.:Cancerstatistics,2020.CACancerJ.Clin.70(1),7–30(2020)</ref-fulltext> 
<ce:source-text>Siegel,R.L.,Miller,K.D.,Jemal,A.:Cancerstatistics,2020.CACancerJ.Clin.70(1),7–30(2020)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines and advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Dunlop</ce:surname>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>Campbell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag.</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dunlop,R.J.,Campbell,C.W.:Cytokines and advanced cancer.J.Pain Symptom Manag.20(3),214–232(2000)</ref-fulltext>
<ce:source-text>Dunlop,R.J.,Campbell,C.W.:Cytokines and advanced cancer.J.Pain Symptom Manag.20(3),214–232(2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman,R.E.,etal.:Bone metastases. Nat.Rev.Dis.Primers.6(1),83(2020)</ref-fulltext>
<ce:source-text>Coleman,R.E.,etal.:Bone metastases. Nat.Rev.Dis.Primers.6(1),83(2020)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.K.</ce:initials>
<ce:surname>Hernandez</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hernandez, R.K.,etal.:Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer.18(1),44(2018)</ref-fulltext>
<ce:source-text>Hernandez, R.K.,etal.:Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States. BMC Cancer.18(1),44(2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical features of metastatic bone disease and risk of skeletal morbidity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res.</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>20 Pt 2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6243s</first-page>
<last-page>6249s</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20Pt2),6243s–6249s(2006)</ref-fulltext>
<ce:source-text>Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20Pt2),6243s–6249s(2006)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of myeloma bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biochem.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-text></ref-text>
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>283</first-page>
<last-page>291</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roodman,G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2),283–291(2010)</ref-fulltext>
<ce:source-text>Roodman,G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2),283–291(2010)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal complications of malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1588</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E. :Skeletal complications of malignancy. Cancer. 80(8Suppl), 1588–1594(1997)</ref-fulltext>
<ce:source-text>Coleman, R.E. :Skeletal complications of malignancy. Cancer. 80(8Suppl), 1588–1594(1997)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev.</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>98</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ref-fulltext> 
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: a fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the bone in cancer metastasis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fornetti</ce:surname>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Welm</ce:surname>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res.</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2099</first-page>
<last-page>2113</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ref-fulltext> 
<ce:source-text>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of bone remodeling.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Raggatt</ce:surname>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Partridge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> J. Biol. Chem.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25103</first-page>
<last-page>25108</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ref-fulltext> 
<ce:source-text>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells interact with osteoblasts to support osteoclast formation.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinology.</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4451</first-page>
<last-page>4458</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ref-fulltext>
<ce:source-text>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> J. Clin. Invest.</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english> Metastasis to bone: causes, consequences and therapeutic opportunities.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> Nat. Rev. Cancer.</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies to target TGF-beta in the treatment of bone metastases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Buijs</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Juarez</ce:surname>
</author>
<author seq="">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> Curr. Pharm. Biotechnol.</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2121</first-page>
<last-page>2137</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ref-fulltext>
<ce:source-text>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english> Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol.</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ref-fulltext> 
<ce:source-text>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.N.</ce:initials>
<ce:surname>Hortobagyi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. </ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1785</first-page>
<last-page>1791</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ref-fulltext> 
<ce:source-text>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Berenson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Myeloma Aredia Study
Group. N. Engl. J. Med.</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>334</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>488</first-page>
<last-page>493</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ref-fulltext> 
<ce:source-text>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Reddington</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Surg. Neurol. Int.</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<iss-first>13</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>361</first-page>
<last-page>365</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ref-fulltext> 
<ce:source-text>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>69</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ref-fulltext> 
<ce:source-text>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>: Usefulness of radium-223 in patients with bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Proc. (Bayl. Univ. Med. Cent.)</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>424</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ref-fulltext> 
<ce:source-text>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Autzen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer.</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1219</first-page>
<last-page>1223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext> Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ref-fulltext> 
<ce:source-text> Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle> Proc. Natl. Acad. Sci. USA.</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10954</first-page>
<last-page>10959</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.B.</ce:initials>
<ce:surname>Nelson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>944</first-page>
<last-page>949</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ref-fulltext> 
<ce:source-text>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.F.</ce:initials>
<ce:surname>Shariat</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>J. Clin. Oncol.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2856</first-page>
<last-page>2864</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ref-fulltext>
<ce:source-text>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Jiao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1177</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ref-fulltext> 
<ce:source-text>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts in prostate cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Logothetis</ce:surname>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text> Nat. Rev. Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ref-fulltext> 
<ce:source-text>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Asadi</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>Hum. Pathol.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1319</first-page>
<last-page>1323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ref-fulltext> 
<ce:source-text>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Schluter</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Katzer</ce:surname>
</author>
<author seq="3">
<ce:initials>H.M.</ce:initials>
<ce:surname>Piper</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Br. J. Pharmacol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>427</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ref-fulltext> 
<ce:source-text>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrPreceptor binding domain activates cardiac ET (A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Clin. Cancer Res.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2922</first-page>
<last-page>2932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Wright</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Oncotarget</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8406</first-page>
<last-page>8419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ref-fulltext> 
<ce:source-text>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptornegative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Endocr. Relat. Cancer.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>769</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ref-fulltext> 
<ce:source-text>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia in the context of metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Biswas</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Nat. Rev. Cancer.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ref-fulltext> 
<ce:source-text>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: an international consensus.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Lancet Oncol.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext> 
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence, incidence and clinical impact of cachexia: facts and numbers-update</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbersupdate 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ref-fulltext>
<ce:source-text>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbersupdate 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nutr. Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ref-fulltext> 
<ce:source-text>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english> Cancer-associated cachexia.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Nat. Rev. Dis. Primers.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext> 
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2000"/>
<ref-text>J. Am. Geriatr. Soc.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ref-fulltext> 
<ce:source-text>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Newman</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text> J. Gerontol. A Biol. Sci. Med. Sci.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ref-fulltext> 
<ce:source-text>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Goodpaster</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>J. Gerontol. A Biol. Sci. Med. Sci.</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1059</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ref-fulltext> 
<ce:source-text>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and fitness in women with metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Yee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>J. Cancer Surviv</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>647</first-page>
<last-page>656</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ref-fulltext>
<ce:source-text>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Breast Cancer Res.Treat</ref-text>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>172</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Moreau</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Cancer Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3677</first-page>
<last-page>3684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ref-fulltext>
<ce:source-text>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Prostate Cancer Prostatic Dis</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>198</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ref-fulltext>
<ce:source-text>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Daly</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>325</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ref-fulltext>
<ce:source-text>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J. Clin. Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1054</first-page>
<last-page>1060</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ref-fulltext>
<ce:source-text>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Cancers (Basel)</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ref-fulltext>
<ce:source-text>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>J. Bone Miner. Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Semin. Cell Dev. Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ref-fulltext>
<ce:source-text>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Endocrine regulation of energy metabolism by the skeleton</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>456</first-page>
<last-page>469</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ref-fulltext>
<ce:source-text>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Riquelme-Gallego</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Sci. Rep</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1840</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ref-fulltext>
<ce:source-text>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Levinger</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ref-fulltext>
<ce:source-text>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ref-fulltext>
<ce:source-text>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Nat. Genet</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2001"/>
<ref-text>Genes Dev</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Narola</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Plos One</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ref-fulltext>
<ce:source-text>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aberrant repair and fibrosis development in skeletal muscle.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Mann</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Skelet. Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ref-fulltext>
<ce:source-text>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Biochem. Biophys. Res. Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5266</first-page>
<last-page>5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>J. Biol. Chem</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Nat. Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>757</first-page>
<last-page>765</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ref-fulltext>
<ce:source-text>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Erlebacher</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>J. Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>195</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ref-fulltext>
<ce:source-text>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Plos One</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ref-fulltext>
<ce:source-text>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2003"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Nat. Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat. Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Nat. Med</ref-text>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>  4th chap
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Targeting Metastatic Disease: Challenges and New Opportunities</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Haitian</ce:given-name>
</author>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Zeping</ce:given-name>
</author>
<affiliation>
<organization>School of Pharmaceutical Sciences</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<author-group seq="3">
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
<ce:e-address>hanzheng@tsinghua.edu.cn</ce:e-address>
</author>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Metastasis is the major cause of cancer-associated deaths in most cancers. Research in the past two decades revealed the complexity of metastasis process. Metastasis involved not only tumor-intrinsic signaling, but often their interactions with tumor microenvironment composed of extracellular matrix and stromal cells including fibroblast, endothelial cells, macrophages etc. Tumor immune environment and cancer metabolism shunting also contribute to metastasis cascade. Lagging this mechanistic understanding of metastatic cascade is the scarce of effective therapeutic options specifically designed for metastatic patients. A few successful treatment examples include bisphosphonate and denosumab against bone metastasis, immune checkpoint inhibitors for certain metastatic cancer patients. In this chapter, we will discuss the approved therapeutic agents and procedures for metastatic patients and discuss the current progress on metastasis research that could shed light upon future drug development.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>51</first-page>
<last-page>68</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="159">
<reference seq="1">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Wild</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Weiderpass</ce:surname>
</author>
<author seq="3">
<ce:initials>B.W.</ce:initials>
<ce:surname>Stewart</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>World Cancer Report: Cancer Research for Cancer Prevention</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention.</ref-fulltext>
<ce:source-text>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention.</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1970"/>
<ref-text>J Natl Cancer Inst</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>773</first-page>
<last-page>782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ref-fulltext>
<ce:source-text>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Dissemination and growth of cancer cells in metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.F.</ce:initials>
<ce:surname>Chambers</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Groom</ce:surname>
</author>
<author seq="3">
<ce:initials>I.C.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>563</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ref-fulltext>
<ce:source-text>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.S.</ce:initials>
<ce:surname>Steeg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Nature Reviews Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>201</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ref-fulltext>
<ce:source-text>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: Causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>Nature Reviews Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: A fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Nature Reviews Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Bone metastasis and the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Journal of Molecular Medicine</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1203</first-page>
<last-page>1212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ref-fulltext>
<ce:source-text>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1889"/>
<ref-text>Lancet</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>SnapShot: Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ell</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>151</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ref-fulltext>
<ce:source-text>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Endocrinol Metab (Seoul)</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>206</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ref-fulltext>
<ce:source-text>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of bone metastasis and associated muscle weakness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Clin Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3071</first-page>
<last-page>3077</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ref-fulltext>
<ce:source-text>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Juppner</ce:surname>
</author>
<author seq="2">
<ce:initials>A.B.</ce:initials>
<ce:surname>Abou-Samra</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Freeman</ce:surname>
</author>
<author seq="4">
<ce:initials>X.F.</ce:initials>
<ce:surname>Kong</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Schipani</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Richards</ce:surname>
</author>
<author seq="7">
<ce:initials>L.F.</ce:initials>
<ce:surname>Kolakowski</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Hock</ce:surname>
</author>
<author seq="9">
<ce:initials>J.T.</ce:initials>
<ce:surname>Potts</ce:surname>
</author>
<author seq="10">
<ce:initials>H.M.</ce:initials>
<ce:surname>Kronenberg</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>254</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1024</first-page>
<last-page>1026</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski Jr., L.F., Hock, J., Potts Jr., J.T., Kronenberg, H.M., et al.: A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254, 1024–1026 (1991)</ref-fulltext>
<ce:source-text>Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski Jr., L.F., Hock, J., Potts Jr., J.T., Kronenberg, H.M., et al.: A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254, 1024–1026 (1991)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Dai</ce:surname>
</author>
<author seq="3">
<ce:initials>C.G.</ce:initials>
<ce:surname>Winter</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Kohno</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Aogi</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Minami</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Nakamura</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asaga</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Iino</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Watanabe</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Goessl</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ohashi</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Takashima</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>J Clin Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3314</first-page>
<last-page>3321</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ref-fulltext>
<ce:source-text>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab and bisphosphonates: Different mechanisms of action and effects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Baron</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ferrari</ce:surname>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Russell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>677</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011)</ref-fulltext>
<ce:source-text>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fizazi</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Carducci</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Damiao</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Karsh</ce:surname>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:surname>Milecki</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Shore</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Rader</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>813</first-page>
<last-page>822</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 377, 813–822 (2011)</ref-fulltext>
<ce:source-text>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 377, 813–822 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Body</ce:surname>
</author>
<author seq="4">
<ce:initials>G.G.</ce:initials>
<ce:surname>Steger</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Tonkin</ce:surname>
</author>
<author seq="6">
<ce:initials>R.H.</ce:initials>
<ce:surname>de Boer</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Lichinitser</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Fujiwara</ce:surname>
</author>
<author seq="9">
<ce:initials>D.A.</ce:initials>
<ce:surname>Yardley</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Viniegra</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J Clin Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Durgeau</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Virk</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Corgnac</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Mami-Chouaib</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front Immunol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ref-fulltext>
<ce:source-text>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>CD8(+) T cell states in human cancer: Insights from single-cell analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Van der Leun</ce:surname>
</author>
<author seq="2">
<ce:initials>D.S.</ce:initials>
<ce:surname>Thommen</ce:surname>
</author>
<author seq="3">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>218</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.: CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ref-fulltext>
<ce:source-text>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.: CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Immune evasion in cancer: Mechanistic basis and therapeutic strategies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Vinay</ce:surname>
</author>
<author seq="2">
<ce:initials>E.P.</ce:initials>
<ce:surname>Ryan</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pawelec</ce:surname>
</author>
<author seq="4">
<ce:initials>W.H.</ce:initials>
<ce:surname>Talib</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Stagg</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:surname>Elkord</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Lichtor</ce:surname>
</author>
<author seq="8">
<ce:initials>W.K.</ce:initials>
<ce:surname>Decker</ce:surname>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Whelan</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Kumara</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Semin Cancer Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>S185</first-page>
<last-page>S198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185–S198 (2015)</ref-fulltext>
<ce:source-text>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185–S198 (2015)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Current issues and perspectives in PD-1 blockade cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Chamoto</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Hatae</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Honjo</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Int J Clin Oncol</ref-text>
</ref-info>
<ref-fulltext>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ref-fulltext>
<ce:source-text>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of T cell co-stimulation and co- inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.B.</ce:initials>
<ce:surname>Flies</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Nat Rev Immunol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>227</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ref-fulltext>
<ce:source-text>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting the mechanisms of immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Sharma</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Nat Rev Immunol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>75</first-page>
<last-page>76</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ref-fulltext>
<ce:source-text>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Immune checkpoint inhibitors of PD-L1 as cancer therapeutics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Akinleye</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Rasool</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J Hematol Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>92</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ref-fulltext>
<ce:source-text>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Improved survival with ipilimumab in patients with metastatic melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>O'day</ce:surname>
</author>
<author seq="3">
<ce:initials>D.F.</ce:initials>
<ce:surname>McDermott</ce:surname>
</author>
<author seq="4">
<ce:initials>R.W.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sosman</ce:surname>
</author>
<author seq="6">
<ce:initials>J.B.</ce:initials>
<ce:surname>Haanen</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Robert</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
</author>
<author seq="10">
<ce:initials>J.C.</ce:initials>
<ce:surname>Hassel</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>N Engl J Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>723</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ref-fulltext>
<ce:source-text>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>McDermott</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Lebbe</ce:surname>
</author>
<author seq="3">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maio</ce:surname>
</author>
<author seq="5">
<ce:initials>J.S.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="6">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Balch</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Cancer Treat Rev</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ref-fulltext>
<ce:source-text>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Chiarion-Sileni</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Rutkowski</ce:surname>
</author>
<author seq="5">
<ce:initials>J.J.</ce:initials>
<ce:surname>Grob</ce:surname>
</author>
<author seq="6">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cowey</ce:surname>
</author>
<author seq="7">
<ce:initials>C.D.</ce:initials>
<ce:surname>Lao</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Wagstaff</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
</author>
<author seq="10">
<ce:initials>P.F.</ce:initials>
<ce:surname>Ferrucci</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>N Engl J Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1345</first-page>
<last-page>1356</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ref-fulltext>
<ce:source-text>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hara</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Fukuoka</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Takahashi</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Kojima</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Kawazoe</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Asayama</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshii</ce:surname>
</author>
<author seq="8">
<ce:initials>D.</ce:initials>
<ce:surname>Kotani</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Tamura</ce:surname>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Mikamoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Ann Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ref-fulltext>
<ce:source-text>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>CAR T cell therapy: Inroads to response and resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mackall</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Nat Rev Immunol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>73</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ref-fulltext>
<ce:source-text>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Engineered T cells: The promise and challenges of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Fesnak</ce:surname>
</author>
<author seq="2">
<ce:initials>C.H.</ce:initials>
<ce:surname>June</ce:surname>
</author>
<author seq="3">
<ce:initials>B.L.</ce:initials>
<ce:surname>Levine</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>566</first-page>
<last-page>581</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ref-fulltext>
<ce:source-text>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer vaccines: Between the idea and the reality</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.J.</ce:initials>
<ce:surname>Finn</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2003"/>
<ref-text>Nat Rev Immunol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>630</first-page>
<last-page>641</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ref-fulltext>
<ce:source-text>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized vaccines for cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Tureci</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>359</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1355</first-page>
<last-page>1360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ref-fulltext>
<ce:source-text>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>An immunogenic personal neoantigen vaccine for patients with melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.A.</ce:initials>
<ce:surname>Ott</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="3">
<ce:initials>D.B.</ce:initials>
<ce:surname>Keskin</ce:surname>
</author>
<author seq="4">
<ce:initials>S.A.</ce:initials>
<ce:surname>Shukla</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Bozym</ce:surname>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Luoma</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Giobbie-Hurder</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Peter</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>217</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ref-fulltext>
<ce:source-text>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Derhovanessian</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="4">
<ce:initials>B.P.</ce:initials>
<ce:surname>Kloke</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Simon</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lower</ce:surname>
</author>
<author seq="7">
<ce:initials>V.</ce:initials>
<ce:surname>Bukur</ce:surname>
</author>
<author seq="8">
<ce:initials>A.D.</ce:initials>
<ce:surname>Tadmor</ce:surname>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Luxemburger</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Schrors</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>222</first-page>
<last-page>226</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ref-fulltext>
<ce:source-text>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neoantigens in Cancer Immunotherapy</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-text>Science</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>348</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ref-fulltext>
<ce:source-text>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.K.</ce:initials>
<ce:surname>Hong</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Macintyre</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Wedge</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>van Loo</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lunke</ce:surname>
</author>
<author seq="7">
<ce:initials>L.B.</ce:initials>
<ce:surname>Alexandrov</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Sloggett</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Cmero</ce:surname>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Marass</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6605</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ref-fulltext>
<ce:source-text>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Vermaat</ce:surname>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Nijman</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Koudijs</ce:surname>
</author>
<author seq="4">
<ce:initials>F.L.</ce:initials>
<ce:surname>Gerritse</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Scherer</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Mokry</ce:surname>
</author>
<author seq="7">
<ce:initials>W.M.</ce:initials>
<ce:surname>Roessingh</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Lansu</ce:surname>
</author>
<author seq="9">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
</author>
<author seq="10">
<ce:initials>R.</ce:initials>
<ce:surname>van Hillegersberg</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Clin Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>688</first-page>
<last-page>699</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ref-fulltext>
<ce:source-text>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Activating ESR1 mutations in hormone-resistant metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Robinson</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Vats</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Su</ce:surname>
</author>
<author seq="5">
<ce:initials>R.J.</ce:initials>
<ce:surname>Lonigro</ce:surname>
</author>
<author seq="6">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Kalyana-Sundaram</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ning</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Hodges</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Nat Genet</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1446</first-page>
<last-page>1451</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ref-fulltext>
<ce:source-text>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Toy</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Won</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Green</ce:surname>
</author>
<author seq="5">
<ce:initials>R.A.</ce:initials>
<ce:surname>Sakr</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Will</ce:surname>
</author>
<author seq="7">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Gala</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Fanning</ce:surname>
</author>
<author seq="10">
<ce:initials>T.A.</ce:initials>
<ce:surname>King</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Nat Genet</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1439</first-page>
<last-page>1445</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ref-fulltext>
<ce:source-text>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.L.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hancock</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Gersch</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Larios</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>David</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="8">
<ce:initials>D.F.</ce:initials>
<ce:surname>Hayes</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="10">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rae</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Breast Cancer Res Treat</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>611</first-page>
<last-page>622</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ref-fulltext>
<ce:source-text>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Pan-cancer whole-genome analyses of metastatic solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Priestley</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Baber</ce:surname>
</author>
<author seq="3">
<ce:initials>M.P.</ce:initials>
<ce:surname>Lolkema</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Steeghs</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Shale</ce:surname>
</author>
<author seq="7">
<ce:initials>K.</ce:initials>
<ce:surname>Duyvesteyn</ce:surname>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Haidari</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>van Hoeck</ce:surname>
</author>
<author seq="10">
<ce:initials>W.</ce:initials>
<ce:surname>Onstenk</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>575</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>210</first-page>
<last-page>216</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ref-fulltext>
<ce:source-text>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Ferrara</ce:surname>
</author>
<author seq="2">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hillan</ce:surname>
</author>
<author seq="3">
<ce:initials>H.P.</ce:initials>
<ce:surname>Gerber</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Novotny</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>Nat Rev Drug Discov</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>400</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ref-fulltext>
<ce:source-text>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Bevacizumab: A review of its use in metastatic colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.L.</ce:initials>
<ce:surname>McCormack</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Keam</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Drugs</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>506</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ref-fulltext>
<ce:source-text>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ebos</ce:surname>
</author>
<author seq="2">
<ce:initials>C.R.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Cruz-Munoz</ce:surname>
</author>
<author seq="4">
<ce:initials>G.A.</ce:initials>
<ce:surname>Bjarnason</ce:surname>
</author>
<author seq="5">
<ce:initials>J.G.</ce:initials>
<ce:surname>Christensen</ce:surname>
</author>
<author seq="6">
<ce:initials>R.S.</ce:initials>
<ce:surname>Kerbel</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>232</first-page>
<last-page>239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ref-fulltext>
<ce:source-text>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Loges</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Mazzone</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Hohensinner</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Carmeliet</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>167</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ref-fulltext>
<ce:source-text>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: From dissemination to organ- specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a Distance: Organ-Specific Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging Biological Principles of Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment and survivorship statistics, 2019</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Nogueira</ce:surname>
</author>
<author seq="3">
<ce:initials>A.B.</ce:initials>
<ce:surname>Mariotto</ce:surname>
</author>
<author seq="4">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
</author>
<author seq="5">
<ce:initials>K.R.</ce:initials>
<ce:surname>Yabroff</ce:surname>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Alfano</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
<author seq="8">
<ce:initials>J.L.</ce:initials>
<ce:surname>Kramer</ce:surname>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>CA Cancer J Clin</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ref-fulltext>
<ce:source-text>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Early dissemination seeds metastasis in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
</author>
<author seq="2">
<ce:initials>M.M.S.</ce:initials>
<ce:surname>Obradovic</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Hoffmann</ce:surname>
</author>
<author seq="4">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Werner-Klein</ce:surname>
</author>
<author seq="7">
<ce:initials>L.K.</ce:initials>
<ce:surname>Nanduri</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Werno</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ehrl</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Maneck</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>552</first-page>
<last-page>558</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ref-fulltext>
<ce:source-text>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative evidence for early metastatic seeding in colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Seoane</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Scott Shaffer</ce:surname>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Suarez</ce:surname>
</author>
<author seq="8">
<ce:initials>A.S.</ce:initials>
<ce:surname>Berghoff</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Cremolini</ce:surname>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Falcone</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Nat Genet</ref-text>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1113</first-page>
<last-page>1122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ref-fulltext>
<ce:source-text>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cancer Discov</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>974</first-page>
<last-page>975</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating epithelial cells in patients with benign colon diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Deneve</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Nocca</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Coffy</ce:surname>
</author>
<author seq="5">
<ce:initials>J.P.</ce:initials>
<ce:surname>Vendrell</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Maudelonde</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Clin Chem</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>936</first-page>
<last-page>940</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>EMT and dissemination precede pancreatic tumor formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Rhim</ce:surname>
</author>
<author seq="2">
<ce:initials>E.T.</ce:initials>
<ce:surname>Mirek</ce:surname>
</author>
<author seq="3">
<ce:initials>N.M.</ce:initials>
<ce:surname>Aiello</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Maitra</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bailey</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>McAllister</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Reichert</ce:surname>
</author>
<author seq="8">
<ce:initials>G.L.</ce:initials>
<ce:surname>Beatty</ce:surname>
</author>
<author seq="9">
<ce:initials>A.K.</ce:initials>
<ce:surname>Rustgi</ce:surname>
</author>
<author seq="10">
<ce:initials>R.H.</ce:initials>
<ce:surname>Vonderheide</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>148</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>349</first-page>
<last-page>361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ref-fulltext>
<ce:source-text>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Dongre</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Nat Rev Mol Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>84</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ref-fulltext>
<ce:source-text>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Classifying collective cancer cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Friedl</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Locker</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Sahai</ce:surname>
</author>
<author seq="4">
<ce:initials>J.E.</ce:initials>
<ce:surname>Segall</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>777</first-page>
<last-page>783</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ref-fulltext>
<ce:source-text>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Adjuvant CMF chemotherapy in operable breast cancer: Ten years later</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Bonadonna</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Rossi</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Valagussa</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1985"/>
<ref-text>Lancet</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>976</first-page>
<last-page>977</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ref-fulltext>
<ce:source-text>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Foss</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Munoz-Sagredo</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sleeman</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Thiele</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Clin Exp Metastasis</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>47</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ref-fulltext>
<ce:source-text>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Padua</ce:surname>
</author>
<author seq="2">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Nadal</ce:surname>
</author>
<author seq="5">
<ce:initials>W.L.</ce:initials>
<ce:surname>Gerald</ce:surname>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Gomis</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>66</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ref-fulltext>
<ce:source-text>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Dormant tumour cells, their niches and the influence of immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.T.</ce:initials>
<ce:surname>Goddard</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Bozic</ce:surname>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Riddell</ce:surname>
</author>
<author seq="4">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1240</first-page>
<last-page>1249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ref-fulltext>
<ce:source-text>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="3">
<ce:initials>T.L.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Tesic Mark</ce:surname>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Molina</ce:surname>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Kohsaka</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Di Giannatale</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Ceder</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Murgai</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Ju</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Eason</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Kline</ce:surname>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Beury</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaczanowska</ce:surname>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Miettinen</ce:surname>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Kruhlak</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Lei</ce:surname>
</author>
<author seq="10">
<ce:initials>J.F.</ce:initials>
<ce:surname>Shern</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Nat Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1176</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ref-fulltext>
<ce:source-text>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Aleckovic</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lavotshkin</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Moreno-Bueno</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Hergueta-Redondo</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Williams</ce:surname>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Garcia-Santos</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Nat Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
</author>
<author seq="4">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Steiner</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Freitas</ce:surname>
</author>
<author seq="7">
<ce:initials>H.S.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>P.R.</ce:initials>
<ce:surname>Oxley</ce:surname>
</author>
<author seq="9">
<ce:initials>I.</ce:initials>
<ce:surname>Scandariato</ce:surname>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Casanova-Salas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Dormancy in solid tumors: Implications for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.S.</ce:initials>
<ce:surname>Ruppender</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Morrissey</ce:surname>
</author>
<author seq="3">
<ce:initials>P.H.</ce:initials>
<ce:surname>Lange</ce:surname>
</author>
<author seq="4">
<ce:initials>R.L.</ce:initials>
<ce:surname>Vessella</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Cancer Metastasis Rev</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>509</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ref-fulltext>
<ce:source-text>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis dormancy in estrogen receptor-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Giuliano</ce:surname>
</author>
<author seq="3">
<ce:initials>M.V.</ce:initials>
<ce:surname>Trivedi</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Schiff</ce:surname>
</author>
<author seq="5">
<ce:initials>C.K.</ce:initials>
<ce:surname>Osborne</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Clin Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6389</first-page>
<last-page>6397</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ref-fulltext>
<ce:source-text>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Aslakson</ce:surname>
</author>
<author seq="2">
<ce:initials>F.R.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1992"/>
<ref-text>Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1399</first-page>
<last-page>1405</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ref-fulltext>
<ce:source-text>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Shu</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Drobnjak</ce:surname>
</author>
<author seq="5">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Cordon-Cardo</ce:surname>
</author>
<author seq="7">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2003"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Mu</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Hua</ce:surname>
</author>
<author seq="9">
<ce:initials>B.J.</ce:initials>
<ce:surname>Tiede</ce:surname>
</author>
<author seq="10">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ref-fulltext>
<ce:source-text>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>The Relationship Between Dormant Cancer Cells and Their Microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Linde</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Fluegen</ce:surname>
</author>
<author seq="3">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Adv Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>71</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ref-fulltext>
<ce:source-text>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Models, mechanisms and clinical evidence for cancer dormancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>834</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanism of early dissemination and metastasis in Her2(+) mammary cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
</author>
<author seq="2">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Entenberg</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
</author>
<author seq="5">
<ce:initials>J.F.</ce:initials>
<ce:surname>Cheung</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Nobre</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Avivar-Valderas</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Nagi</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Girnius</ce:surname>
</author>
<author seq="10">
<ce:initials>R.J.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>588</first-page>
<last-page>592</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ref-fulltext>
<ce:source-text>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Holzmann</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Gottlinger</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Schmidt</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Hauser</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Swierkot</ce:surname>
</author>
<author seq="8">
<ce:initials>H.H.</ce:initials>
<ce:surname>Warnecke</ce:surname>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Schneider</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Koprowski</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1987"/>
<ref-text>Proc Natl Acad Sci U S A</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>84</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8672</first-page>
<last-page>8676</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ref-fulltext>
<ce:source-text>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic niche functions and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Celia-Terrassa</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>868</first-page>
<last-page>877</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ref-fulltext>
<ce:source-text>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis prevention by targeting the dormant niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>238</first-page>
<last-page>247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ref-fulltext>
<ce:source-text>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiozawa</ce:surname>
</author>
<author seq="2">
<ce:initials>E.A.</ce:initials>
<ce:surname>Pedersen</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Havens</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Jung</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Mishra</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Joseph</ce:surname>
</author>
<author seq="7">
<ce:initials>J.K.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>L.R.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ying</ce:surname>
</author>
<author seq="10">
<ce:initials>A.M.</ce:initials>
<ce:surname>Ziegler</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>J Clin Invest</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1298</first-page>
<last-page>1312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ref-fulltext>
<ce:source-text>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Lawson</ce:surname>
</author>
<author seq="2">
<ce:initials>M.M.</ce:initials>
<ce:surname>McDonald</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kovacic</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Hua Khoo</ce:surname>
</author>
<author seq="5">
<ce:initials>R.L.</ce:initials>
<ce:surname>Terry</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Down</ce:surname>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Kaplan</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Paton-Hough</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Fellows</ce:surname>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Pettitt</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8983</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ref-fulltext>
<ce:source-text>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Goldstein</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Bado</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>B.R.</ce:initials>
<ce:surname>Arenkiel</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>823</iss-first>
<iss-last>839</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ref-fulltext>
<ce:source-text>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Welte</ce:surname>
</author>
<author seq="5">
<ce:initials>A.M.</ce:initials>
<ce:surname>Muscarella</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Tao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Cancer Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ref-fulltext>
<ce:source-text>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Bae</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kasimir-Bauer</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Cancer Cell</ref-text>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>731</iss-first>
<iss-last>747</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ref-fulltext>
<ce:source-text>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>231</first-page>
<last-page>235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ref-fulltext>
<ce:source-text>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>The bone marrow niche for haematopoietic stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="2">
<ce:initials>D.T.</ce:initials>
<ce:surname>Scadden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>505</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>327</first-page>
<last-page>334</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ref-fulltext>
<ce:source-text>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of chemokine receptors in breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Muller</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Ge</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Catron</ce:surname>
</author>
<author seq="6">
<ce:initials>M.E.</ce:initials>
<ce:surname>Buchanan</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>McClanahan</ce:surname>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="10">
<ce:initials>S.N.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>410</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>50</first-page>
<last-page>56</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ref-fulltext>
<ce:source-text>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Homeostatic chemokine receptors and organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zlotnik</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Burkhardt</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Nat Rev Immunol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>597</first-page>
<last-page>606</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ref-fulltext>
<ce:source-text>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lee-Lim</ce:surname>
</author>
<author seq="4">
<ce:initials>Q.</ce:initials>
<ce:surname>Mo</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Decker</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Vonica</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Brogi</ce:surname>
</author>
<author seq="9">
<ce:initials>A.H.</ce:initials>
<ce:surname>Brivanlou</ce:surname>
</author>
<author seq="10">
<ce:initials>F.G.</ce:initials>
<ce:surname>Giancotti</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>150</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>764</first-page>
<last-page>779</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ref-fulltext>
<ce:source-text>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Niches for Hematopoietic Stem Cells and Their Progeny</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="2">
<ce:initials>P.S.</ce:initials>
<ce:surname>Frenette</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>632</first-page>
<last-page>648</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ref-fulltext>
<ce:source-text>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mignatti</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Kovalski</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Ossowski</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2001"/>
<ref-text>Mol Biol Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>863</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Kobayashi</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Okuda</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Pandey</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Watabe</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hirota</ce:surname>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Pai</ce:surname>
</author>
<author seq="8">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="9">
<ce:initials>K.</ce:initials>
<ce:surname>Fukuda</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Chambers</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>J Exp Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>208</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2641</first-page>
<last-page>2655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ref-fulltext>
<ce:source-text>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bragado</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Estrada</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Parikh</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Krause</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Capobianco</ce:surname>
</author>
<author seq="6">
<ce:initials>H.G.</ce:initials>
<ce:surname>Farina</ce:surname>
</author>
<author seq="7">
<ce:initials>D.M.</ce:initials>
<ce:surname>Schewe</ce:surname>
</author>
<author seq="8">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1351</first-page>
<last-page>1361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ref-fulltext>
<ce:source-text>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Catena</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>El Rayes</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Choi</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Ryu</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Joshi</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Bielenberg</ce:surname>
</author>
<author seq="10">
<ce:initials>S.B.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Cancer Discov</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ref-fulltext>
<ce:source-text>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.W.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="2">
<ce:initials>E.C.</ce:initials>
<ce:surname>Finger</ce:surname>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Olcina</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Vilalta</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Aguilera</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Miao</ce:surname>
</author>
<author seq="7">
<ce:initials>A.R.</ce:initials>
<ce:surname>Merkel</ce:surname>
</author>
<author seq="8">
<ce:initials>J.R.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="9">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sterling</ce:surname>
</author>
<author seq="10">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1078</first-page>
<last-page>1089</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ref-fulltext>
<ce:source-text>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Metastases in immune-mediated dormancy: A new opportunity for targeting cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Romero</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Garrido</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Garcia-Lora</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6750</first-page>
<last-page>6757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ref-fulltext>
<ce:source-text>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Malladi</ce:surname>
</author>
<author seq="2">
<ce:initials>D.G.</ce:initials>
<ce:surname>Macalinao</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Jin</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Basnet</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zou</ce:surname>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:surname>de Stanchina</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>165</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>60</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ref-fulltext>
<ce:source-text>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Kutter</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Schaller</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Genz</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Wiebecke</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Backmann</ce:surname>
</author>
<author seq="8">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Riethmuller</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1991"/>
<ref-text>Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4712</first-page>
<last-page>4715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ref-fulltext>
<ce:source-text>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Pommier</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Anaparthy</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Memos</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.L.</ce:initials>
<ce:surname>Kelley</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Gouronnec</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Auffray</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Albrengues</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Egeblad</ce:surname>
</author>
<author seq="10">
<ce:initials>C.A.</ce:initials>
<ce:surname>Iacobuzio-Donahue</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<page-information>
<pages>
<first-page>360</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ref-fulltext>
<ce:source-text>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptive immunity maintains occult cancer in an equilibrium state</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Koebel</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Vermi</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Swann</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Zerafa</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Rodig</ce:surname>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Old</ce:surname>
</author>
<author seq="7">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
</author>
<author seq="8">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>450</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>903</first-page>
<last-page>907</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ref-fulltext>
<ce:source-text>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.E.</ce:initials>
<ce:surname>Buroni</ce:surname>
</author>
<author seq="2">
<ce:initials>M.G.</ce:initials>
<ce:surname>Persico</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pasi</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Lodola</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nano</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Aprile</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Anticancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5719</first-page>
<last-page>5730</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ref-fulltext>
<ce:source-text>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha emitter radium-223 and survival in metastatic prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Parker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Nilsson</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Heinrich</ce:surname>
</author>
<author seq="4">
<ce:initials>S.I.</ce:initials>
<ce:surname>Helle</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>O'sullivan</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fossa</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chodacki</ce:surname>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Wiechno</ce:surname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Logue</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Seke</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>N Engl J Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>369</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>213</first-page>
<last-page>223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ref-fulltext>
<ce:source-text>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Suominen</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Wilson</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Scholz</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Int J Mol Sci</ref-text>
<volisspag>
<page-information>
<pages>
<first-page>20</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>von Minckwitz</ce:surname>
</author>
<author seq="2">
<ce:initials>C.S.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="3">
<ce:initials>M.S.</ce:initials>
<ce:surname>Mano</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Loibl</ce:surname>
</author>
<author seq="5">
<ce:initials>E.P.</ce:initials>
<ce:surname>Mamounas</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Untch</ce:surname>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Wolmark</ce:surname>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Rastogi</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Schneeweiss</ce:surname>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Redondo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>N Engl J Med</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>380</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>617</first-page>
<last-page>628</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ref-fulltext>
<ce:source-text>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab emtansine: Mechanisms of action and drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barok</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Joensuu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Isola</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Breast Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>209</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ref-fulltext>
<ce:source-text>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="2">
<ce:initials>B.R.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="5">
<ce:initials>H.S.</ce:initials>
<ce:surname>Lai</ce:surname>
</author>
<author seq="6">
<ce:initials>K.W.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="7">
<ce:initials>J.T.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Medicine (Baltimore)</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>95</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ref-fulltext>
<ce:source-text>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Thermal Ablation of Metastatic Colon Cancer to the Liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Camacho</ce:surname>
</author>
<author seq="2">
<ce:initials>E.N.</ce:initials>
<ce:surname>Petre</ce:surname>
</author>
<author seq="3">
<ce:initials>C.T.</ce:initials>
<ce:surname>Sofocleous</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Semin Intervent Radiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>310</first-page>
<last-page>318</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ref-fulltext>
<ce:source-text>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
</author>
<author seq="3">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Metabolic Reprogramming and Cancer Progression</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<page-information>
<pages>
<first-page>368</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>Science (New York, NY)</ref-text>
</ref-info>
<ref-fulltext>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ref-fulltext>
<ce:source-text>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>144</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>646</first-page>
<last-page>674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Science (New York, NY)</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>The Metabolism of Tumors in the Body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Wind</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Negelein</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1927"/>
<ref-text>J Gen Physiol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>530</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ref-fulltext>
<ce:source-text>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomics and Isotope Tracing</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Rabinowitz</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>837</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ref-fulltext>
<ce:source-text>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Applications of metabolomics to study cancer metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Kaushik</ce:surname>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Biochim Biophys Acta Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>1870</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>14</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ref-fulltext>
<ce:source-text>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of cancer cell metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Cairns</ce:surname>
</author>
<author seq="2">
<ce:initials>I.S.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
<author seq="3">
<ce:initials>T.W.</ce:initials>
<ce:surname>Mak</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>85</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ref-fulltext>
<ce:source-text>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Sci Adv</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ref-fulltext>
<ce:source-text>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Intersections between Metabolism and Cancer Biology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>657</first-page>
<last-page>669</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Modelling glandular epithelial cancers in three-dimensional cultures</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Debnath</ce:surname>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Brugge</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Nat Rev Cancer</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>675</first-page>
<last-page>688</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ref-fulltext>
<ce:source-text>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Kishton</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sukumar</ce:surname>
</author>
<author seq="3">
<ce:initials>N.P.</ce:initials>
<ce:surname>Restifo</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ref-fulltext>
<ce:source-text>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends in Cell Biology</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Adaptation Fuels Lymph Node Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>785</first-page>
<last-page>786</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ref-fulltext>
<ce:source-text>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.D.</ce:initials>
<ce:surname>Dinardo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.M.</ce:initials>
<ce:surname>Stein</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>de Botton</ce:surname>
</author>
<author seq="4">
<ce:initials>G.J.</ce:initials>
<ce:surname>Roboz</ce:surname>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Altman</ce:surname>
</author>
<author seq="6">
<ce:initials>A.S.</ce:initials>
<ce:surname>Mims</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Swords</ce:surname>
</author>
<author seq="8">
<ce:initials>R.H.</ce:initials>
<ce:surname>Collins</ce:surname>
</author>
<author seq="9">
<ce:initials>G.N.</ce:initials>
<ce:surname>Mannis</ce:surname>
</author>
<author seq="10">
<ce:initials>D.A.</ce:initials>
<ce:surname>Pollyea</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>The New England Journal of Medicine</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>378</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2386</first-page>
<last-page>2398</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ref-fulltext>
<ce:source-text>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Acetate is a bioenergetic substrate for human glioblastoma and brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mashimo</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Pichumani</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Vemireddy</ce:surname>
</author>
<author seq="4">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hatanpaa</ce:surname>
</author>
<author seq="5">
<ce:initials>D.K.</ce:initials>
<ce:surname>Singh</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sirasanagandla</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Nannepaga</ce:surname>
</author>
<author seq="8">
<ce:initials>S.G.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
</author>
<author seq="9">
<ce:initials>Z.</ce:initials>
<ce:surname>Kovacs</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Foong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1614</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ref-fulltext>
<ce:source-text>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Palmieri</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Menga</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Martin-Perez</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Quinto</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Riera-Domingo</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>de Tullio</ce:surname>
</author>
<author seq="7">
<ce:initials>D.C.</ce:initials>
<ce:surname>Hooper</ce:surname>
</author>
<author seq="8">
<ce:initials>W.H.</ce:initials>
<ce:surname>Lamers</ce:surname>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Ghesquiere</ce:surname>
</author>
<author seq="10">
<ce:initials>D.W.</ce:initials>
<ce:surname>McVicar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Cell Rep</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1654</first-page>
<last-page>1666</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ref-fulltext>
<ce:source-text>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Chiu</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Twu</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ref-fulltext>
<ce:source-text>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>H.J.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Huo</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="9">
<ce:initials>L.R.</ce:initials>
<ce:surname>Bollu</ce:surname>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Cancer Res</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>75</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>565</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ref-fulltext>
<ce:source-text>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Andrzejewski</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Klimcakova</ce:surname>
</author>
<author seq="3">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Tabaries</ce:surname>
</author>
<author seq="5">
<ce:initials>M.G.</ce:initials>
<ce:surname>Annis</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>McGuirk</ce:surname>
</author>
<author seq="7">
<ce:initials>J.J.</ce:initials>
<ce:surname>Northey</ce:surname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Chenard</ce:surname>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Sriram</ce:surname>
</author>
<author seq="10">
<ce:initials>D.J.</ce:initials>
<ce:surname>Papadopoli</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Cell Metab</ref-text>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>778</iss-first>
<iss-last>787</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ref-fulltext>
<ce:source-text>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular Metabolic Energetics Can Promote Cancer Progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Loo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Scherl</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="4">
<ce:initials>F.Y.</ce:initials>
<ce:surname>Man</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
<author seq="6">
<ce:initials>Z.S.</ce:initials>
<ce:surname>Zeng</ce:surname>
</author>
<author seq="7">
<ce:initials>L.</ce:initials>
<ce:surname>Saltz</ce:surname>
</author>
<author seq="8">
<ce:initials>P.B.</ce:initials>
<ce:surname>Paty</ce:surname>
</author>
<author seq="9">
<ce:initials>S.F.</ce:initials>
<ce:surname>Tavazoie</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>160</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>406</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ref-fulltext>
<ce:source-text>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Xiao</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Sugiura</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Kuro-O</ce:surname>
</author>
<author seq="7">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
<author seq="8">
<ce:initials>D.A.</ce:initials>
<ce:surname>Boothman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3908</first-page>
<last-page>3916</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ref-fulltext>
<ce:source-text>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Curtis</ce:surname>
</author>
<author seq="2">
<ce:initials>H.A.</ce:initials>
<ce:surname>Kenny</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Ashcroft</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Mukherjee</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Helou</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Batlle</ce:surname>
</author>
<author seq="9">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="10">
<ce:initials>N.</ce:initials>
<ce:surname>Gutierrez</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Cell Metab</ref-text>
</ref-info>
<ref-fulltext>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ref-fulltext>
<ce:source-text>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Chu</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="7">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>571</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>127</first-page>
<last-page>131</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ref-fulltext>
<ce:source-text>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="4">
<ce:initials>L.L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="5">
<ce:initials>W.M.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="6">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Luo</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.B.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>1107</iss-first>
<iss-last>1119</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ref-fulltext>
<ce:source-text>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>van Weverwijk</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Koundouros</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Iravani</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Ashenden</ce:surname>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Poulogiannis</ce:surname>
</author>
<author seq="7">
<ce:initials>U.</ce:initials>
<ce:surname>Jungwirth</ce:surname>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Isacke</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ref-fulltext>
<ce:source-text>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bu</ce:surname>
</author>
<author seq="2">
<ce:initials>K.Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Xiang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Crown</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Rakhilin</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Ai</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:surname>Xi</ce:surname>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Astapova</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1249</iss-first>
<iss-last>1262</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ref-fulltext>
<ce:source-text>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Corbet</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bastien</ce:surname>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>Santiago de Jesus</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Dierge</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Martherus</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Vander Linden</ce:surname>
</author>
<author seq="7">
<ce:initials>B.</ce:initials>
<ce:surname>Doix</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Degavre</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Guilbaud</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Petit</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>454</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ref-fulltext>
<ce:source-text>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Vithayathil</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
<author seq="4">
<ce:initials>P.L.</ce:initials>
<ce:surname>Sung</ce:surname>
</author>
<author seq="5">
<ce:initials>L.E.</ce:initials>
<ce:surname>Dobrolecki</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Putluri</ce:surname>
</author>
<author seq="7">
<ce:initials>V.B.</ce:initials>
<ce:surname>Bhat</ce:surname>
</author>
<author seq="8">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bhowmik</ce:surname>
</author>
<author seq="9">
<ce:initials>V.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<author seq="10">
<ce:initials>K.</ce:initials>
<ce:surname>Arora</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Cell Rep</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2154</first-page>
<last-page>2165</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ref-fulltext>
<ce:source-text>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis-initiating cells through the fatty acid receptor CD36</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Pascual</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Avgustinova</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Mejetta</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Castellanos</ce:surname>
</author>
<author seq="6">
<ce:initials>C.S.</ce:initials>
<ce:surname>Attolini</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Berenguer</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Prats</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Toll</ce:surname>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Hueto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>541</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ref-fulltext>
<ce:source-text>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Jeong</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Bae</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>I.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>G.Y.</ce:initials>
<ce:surname>Koh</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Science (New York, NY)</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>644</first-page>
<last-page>649</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ref-fulltext>
<ce:source-text>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Hawk</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.T.</ce:initials>
<ce:surname>Schafer</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>J Biol Chem</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>293</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7531</first-page>
<last-page>7537</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ref-fulltext>
<ce:source-text>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Reductive carboxylation supports redox homeostasis during anchorage-independent growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Shestov</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Swain</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Parker</ce:surname>
</author>
<author seq="6">
<ce:initials>Q.A.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="7">
<ce:initials>L.S.</ce:initials>
<ce:surname>Terada</ce:surname>
</author>
<author seq="8">
<ce:initials>N.D.</ce:initials>
<ce:surname>Adams</ce:surname>
</author>
<author seq="9">
<ce:initials>M.T.</ce:initials>
<ce:surname>McCabe</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Pietrak</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>532</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>258</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ref-fulltext>
<ce:source-text>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Oxidative stress inhibits distant metastasis by human melanoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Piskounova</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Agathocleous</ce:surname>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="5">
<ce:initials>S.E.</ce:initials>
<ce:surname>Huddlestun</ce:surname>
</author>
<author seq="6">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="7">
<ce:initials>A.M.</ce:initials>
<ce:surname>Leitch</ce:surname>
</author>
<author seq="8">
<ce:initials>T.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="9">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
<author seq="10">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ref-fulltext>
<ce:source-text>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Antioxidants can increase melanoma metastasis in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
</author>
<author seq="2">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
</author>
<author seq="4">
<ce:initials>V.I.</ce:initials>
<ce:surname>Sayin</ce:surname>
</author>
<author seq="5">
<ce:initials>M.K.</ce:initials>
<ce:surname>Akula</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Karlsson</ce:surname>
</author>
<author seq="7">
<ce:initials>M.G.</ce:initials>
<ce:surname>Dalin</ce:surname>
</author>
<author seq="8">
<ce:initials>L.M.</ce:initials>
<ce:surname>Akyurek</ce:surname>
</author>
<author seq="9">
<ce:initials>P.</ce:initials>
<ce:surname>Lindahl</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Nilsson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Science Translational Medicine</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ref-fulltext>
<ce:source-text>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>Lebleu</ce:surname>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>O'connell</ce:surname>
</author>
<author seq="3">
<ce:initials>K.N.</ce:initials>
<ce:surname>Gonzalez Herrera</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Wikman</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="6">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
</author>
<author seq="7">
<ce:initials>F.M.</ce:initials>
<ce:surname>de Carvalho</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Damascena</ce:surname>
</author>
<author seq="9">
<ce:initials>L.T.</ce:initials>
<ce:surname>Domingos Chinen</ce:surname>
</author>
<author seq="10">
<ce:initials>R.M.</ce:initials>
<ce:surname>Rocha</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Nat Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>992</iss-first>
<iss-text>1003</iss-text>
</volume-issue-number>
<page-information>
<pages>
<first-page>1001</first-page>
<last-page>1015</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ref-fulltext>
<ce:source-text>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Long</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="10">
<ce:initials>Q.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Science Translational Medicine</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ref-fulltext>
<ce:source-text>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
</author>
<author seq="3">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
</author>
<author seq="4">
<ce:initials>C.A.</ce:initials>
<ce:surname>Jahangir</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Kashif</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Yao</ce:surname>
</author>
<author seq="7">
<ce:initials>D.V.</ce:initials>
<ce:surname>Ziegler</ce:surname>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="9">
<ce:initials>T.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="10">
<ce:initials>T.</ce:initials>
<ce:surname>Mondal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>Cell</ref-text>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
<iss-first>330</iss-first>
<iss-last>345</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ref-fulltext>
<ce:source-text>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fischer</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jalali</ce:surname>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Kircher</ce:surname>
</author>
<author seq="4">
<ce:initials>W.C.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="5">
<ce:initials>J.L.</ce:initials>
<ce:surname>McQuade</ce:surname>
</author>
<author seq="6">
<ce:initials>L.E.</ce:initials>
<ce:surname>Haydu</ce:surname>
</author>
<author seq="7">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Joon</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Reuben</ce:surname>
</author>
<author seq="9">
<ce:initials>M.P.</ce:initials>
<ce:surname>de Macedo</ce:surname>
</author>
<author seq="10">
<ce:initials>F.C.L.</ce:initials>
<ce:surname>Carapeto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Cancer Discovery</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>628</first-page>
<last-page>645</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ref-fulltext>
<ce:source-text>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic heterogeneity confers differences in melanoma metastatic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Ramesh</ce:surname>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>577</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>115</first-page>
<last-page>120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ref-fulltext>
<ce:source-text>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lorendeau</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Schmieder</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Metzger</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Veys</ce:surname>
</author>
<author seq="7">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="8">
<ce:initials>J.M.</ce:initials>
<ce:surname>Buescher</ce:surname>
</author>
<author seq="9">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="10">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Cell Reports</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>848</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ref-fulltext>
<ce:source-text>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ngo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Osorio-Vasquez</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Doll</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Bustraan</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Luengo</ce:surname>
</author>
<author seq="8">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
</author>
<author seq="10">
<ce:initials>G.B.</ce:initials>
<ce:surname>Ferraro</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Cancer Discov</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1352</first-page>
<last-page>1373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ref-fulltext>
<ce:source-text>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
</author>
<author seq="2">
<ce:initials>W.Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Alontaga</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Chandra</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ashby</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
</author>
<author seq="8">
<ce:initials>S.T.F.</ce:initials>
<ce:surname>O'connor</ce:surname>
</author>
<author seq="9">
<ce:initials>S.S.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="10">
<ce:initials>A.R.</ce:initials>
<ce:surname>Chin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nature Cell Biology</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2021"/>
<ref-text>Nat Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ref-fulltext>
<ce:source-text>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Modulating the therapeutic response of tumours to dietary serine and glycine starvation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.D.K.</ce:initials>
<ce:surname>Maddocks</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Athineos</ce:surname>
</author>
<author seq="3">
<ce:initials>E.C.</ce:initials>
<ce:surname>Cheung</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="6">
<ce:initials>N.J.F.</ce:initials>
<ce:surname>Van den Broek</ce:surname>
</author>
<author seq="7">
<ce:initials>G.M.</ce:initials>
<ce:surname>Mackay</ce:surname>
</author>
<author seq="8">
<ce:initials>C.F.</ce:initials>
<ce:surname>Labuschagne</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Gay</ce:surname>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Kruiswijk</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>544</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>372</first-page>
<last-page>376</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ref-fulltext>
<ce:source-text>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Serine Is an Essential Metabolite for Effector T Cell Expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Bantug</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Condotta</ce:surname>
</author>
<author seq="5">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Samborska</ce:surname>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Mainolfi</ce:surname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Suri</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Guak</ce:surname>
</author>
<author seq="10">
<ce:initials>M.L.</ce:initials>
<ce:surname>Balmer</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>482</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ref-fulltext>
<ce:source-text>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.G.</ce:initials>
<ce:surname>Roy</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Mamane</ce:surname>
</author>
<author seq="4">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="5">
<ce:initials>B.M.</ce:initials>
<ce:surname>Muhire</ce:surname>
</author>
<author seq="6">
<ce:initials>R.D.</ce:initials>
<ce:surname>Sheldon</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Shorstova</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Koning</ce:surname>
</author>
<author seq="9">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="10">
<ce:initials>E.</ce:initials>
<ce:surname>Esaulova</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>250</iss-first>
<iss-last>266</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ref-fulltext>
<ce:source-text>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Dietary methionine influences therapy in mouse cancer models and alters human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Sanderson</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Dai</ce:surname>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Reid</ce:surname>
</author>
<author seq="5">
<ce:initials>D.E.</ce:initials>
<ce:surname>Cooper</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="7">
<ce:initials>J.P.</ce:initials>
<ce:surname>Richie</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Ciccarella</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Calcagnotto</ce:surname>
</author>
<author seq="10">
<ce:initials>P.G.</ce:initials>
<ce:surname>Mikhael</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>572</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>397</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ref-fulltext>
<ce:source-text>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Creatine promotes cancer metastasis through activation of Smad2/3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="8">
<ce:initials>G.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Cai</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2021"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1111</iss-first>
<iss-last>1123</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ref-fulltext>
<ce:source-text>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Low glycaemic diets alter lipid metabolism to influence tumour growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.</ce:initials>
<ce:surname>Lien</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Westermark</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="6">
<ce:initials>A.N.</ce:initials>
<ce:surname>Lau</ce:surname>
</author>
<author seq="7">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sapp</ce:surname>
</author>
<author seq="8">
<ce:initials>B.M.</ce:initials>
<ce:surname>Wolpin</ce:surname>
</author>
<author seq="9">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>599</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>307</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ref-fulltext>
<ce:source-text>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Nat Commun</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>(b)</ref-text>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Trends Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>  5th chap
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_5</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Signaling Pathways That Promote Muscle Catabolism in Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Gilda</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
<ce:e-address>shenhavc@technion.ac.il</ce:e-address>
</author>
<affiliation>
<organization>Technion-Israel Institute of Technology</organization>
<city>Haifa</city>
<country iso-code="ISR"/>
<ce:source-text>Technion-Israel Institute of Technology, Haifa, Israel</ce:source-text>
</affiliation>
</author-group>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cachexia is a severe loss of muscle mass in chronic disease, often accompanied by metabolic dysfunction, fatigue, loss of appetite, general weight loss, and poor patient outcomes. This debilitating condition is highly prevalent in cancer patients, lowering their quality of life and likelihood of survival. Prevention of muscle loss is expected to prolong survival, however, currently there are no accepted effective treatments, and cachexia is usually only diagnosed in advanced stages when therapeutic intervention is particularly challenging. Development and administration of effective therapies require foundational understanding of the underlying mechanisms that promote protein breakdown and cause wasting. Recently, the sequence of key molecular and cellular events driving catabolism, and the regulatory signals stimulating overall proteolysis, have become clearer from studies on animal models for muscle atrophy. Different types of atrophy share common transcriptional changes and proteolytic pathways that activate degradation of soluble and contractile myofibrillar proteins; consequently, identified key regulators of these common mechanisms should be attractive drug targets for treatment of numerous wasting conditions. In this chapter, we discuss our current knowledge on these catabolic events and key regulators, which orchestrate the continuous progression of the atrophy process from its initial cues. We also highlight promising avenues of research for better understanding and treating cancer cachexia.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: A Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>71</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>01</month>
<day>01</day>
</publicationdate>
<website type="item">
<ce:e-address type="url">https://link.springer.com/</ce:e-address>
</website>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="261">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle regulates metabolism via interorgan crosstalk: Roles in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Campos</ce:surname>
</author>
<author seq="3">
<ce:initials>J.M.</ce:initials>
<ce:surname>Lopez-Pedrosa</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>J. Am. Med. Dir. Assoc</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>796</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Argilés, J.M., Campos, N., Lopez-Pedrosa, J.M., et al.: Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J. Am. Med. Dir. Assoc. 17(9), 789–796 (2016)</ref-fulltext>
<ce:source-text>Argilés, J.M., Campos, N., Lopez-Pedrosa, J.M., et al.: Skeletal muscle regulates metabolism via interorgan crosstalk: roles in health and disease. J. Am. Med. Dir. Assoc. 17(9), 789–796 (2016)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bonaldo</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>DMM Disease Models and Mechanisms</ref-text>
</ref-info>
<ref-fulltext>Bonaldo, P., Sandri, M.: Cellular and molecular mechanisms of muscle atrophy. DMM Disease Models and Mechanisms. (2013)</ref-fulltext>
<ce:source-text>Bonaldo, P., Sandri, M.: Cellular and molecular mechanisms of muscle atrophy. DMM Disease Models and Mechanisms. (2013)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.D.</ce:initials>
<ce:surname>Loberg</ce:surname>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:surname>Bradley</ce:surname>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Tomlins</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>CA Cancer J. Clin</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3322/canjclin.57.4.225</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loberg, R.D., Bradley, D.A., Tomlins, S.A., et al.: The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. CA Cancer J. Clin. (2007). https://doi.org/10.3322/canjclin.57.4.225</ref-fulltext>
<ce:source-text>Loberg, R.D., Bradley, D.A., Tomlins, S.A., et al.: The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy. CA Cancer J. Clin. (2007). https://doi.org/10.3322/canjclin.57.4.225</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis and cachexia: Alongside in clinics, but not so in animal models</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Tomasin</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.B.M.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Cominetti</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J. Cachexia Sarcopenia Muscle</ref-text>
</ref-info>
<ref-fulltext>Tomasin, R., Martin, A.C.B.M., Cominetti, M.R.: Metastasis and cachexia: Alongside in clinics, but not so in animal models. J. Cachexia Sarcopenia Muscle (2019)</ref-fulltext>
<ce:source-text>Tomasin, R., Martin, A.C.B.M., Cominetti, M.R.: Metastasis and cachexia: Alongside in clinics, but not so in animal models. J. Cachexia Sarcopenia Muscle (2019)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.A.</ce:initials>
<ce:surname>Parsons</ce:surname>
</author>
<author seq="2">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Dhillon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Plos One</ref-text>
</ref-info>
<ref-fulltext>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ref-fulltext>
<ce:source-text>Parsons, H.A., Baracos, V.E., Dhillon, N., et al.: Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. (2012)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.J.</ce:initials>
<ce:surname>Tisdale</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Physiol. Rev</ref-text>
</ref-info>
<ref-fulltext>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ref-fulltext>
<ce:source-text>Tisdale, M.J.: Mechanisms of cancer cachexia. Physiol. Rev. (2009)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="2">
<ce:initials>J.L.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Cell</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>142</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>531</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2010.07.011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ref-fulltext>
<ce:source-text>Zhou, X., Wang, J.L., Lu, J., et al.: Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 142, 531–543 (2010). https://doi.org/10.1016/j.cell.2010.07.011</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Orpí</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-publicationyear first="2012"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s13539-011-0049-z</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ref-fulltext>
<ce:source-text>Busquets, S., Toledo, M., Orpí, M., et al.: Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J. Cachexia. Sarcopenia Muscle. (2012). https://doi.org/10.1007/s13539-011-0049-z</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Int. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.29930</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ref-fulltext>
<ce:source-text>Toledo, M., Busquets, S., Penna, F., et al.: Complete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist. Int. J. Cancer. (2016). https://doi.org/10.1002/ijc.29930</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>The metabolic basis of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Alvarez</ce:surname>
</author>
<author seq="3">
<ce:initials>F.J.</ce:initials>
<ce:surname>López-Soriano</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1997"/>
<ref-text>Med. Res. Rev</ref-text>
</ref-info>
<ref-fulltext>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ref-fulltext>
<ce:source-text>Argilés, J.M., Alvarez, B., López-Soriano, F.J.: The metabolic basis of cancer cachexia. Med. Res. Rev. (1997)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cell Metab</ref-text>
</ref-info>
<ref-fulltext>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C.H., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. (2012)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Damrauer</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.</ce:initials>
<ce:surname>Stadler</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Eur. J. Transl. Myol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4081/ejtm.2018.7590</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018.7590</ref-fulltext>
<ce:source-text>Damrauer, J.S., Stadler, M.E., Acharyya, S., et al.: Chemotherapy-induced muscle wasting: Association with NF-κB and cancer cachexia. Eur. J. Transl. Myol. (2018). https://doi.org/10.4081/ejtm.2018.7590</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12360</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12360</ref-fulltext>
<ce:source-text>Pin, F., Barreto, R., Couch, M.E., et al.: Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12360</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Colotta</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Allavena</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Sica</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2009"/>
</ref-info>
<ref-fulltext>Colotta, F., Allavena, P., Sica, A., et al.: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ref-fulltext>
<ce:source-text>Colotta, F., Allavena, P., Sica, A., et al.: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cell</ref-text>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-related inflammation and treatment effectiveness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.I.</ce:initials>
<ce:surname>Diakos</ce:surname>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Charles</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
</author>
<author seq="4">
<ce:initials>S.J.</ce:initials>
<ce:surname>Clarke</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Lancet Oncol</ref-text>
</ref-info>
<ref-fulltext>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ref-fulltext>
<ce:source-text>Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J.: Cancer-related inflammation and treatment effectiveness. Lancet Oncol. (2014)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer and systemic inflammation: Treat the tumour and treat the host</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.S.D.</ce:initials>
<ce:surname>Roxburgh</ce:surname>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Br. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.2014.90</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: Treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/bjc.2014.90</ref-fulltext>
<ce:source-text>Roxburgh, C.S.D., McMillan, D.C.: Cancer and systemic inflammation: Treat the tumour and treat the host. Br. J. Cancer. (2014). https://doi.org/10.1038/bjc.2014.90</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.C.</ce:initials>
<ce:surname>Deans</ce:surname>
</author>
<author seq="2">
<ce:initials>B.H.</ce:initials>
<ce:surname>Tan</ce:surname>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Wigmore</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Br. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.bjc.6604828</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ref-fulltext>
<ce:source-text>Deans, D.A.C., Tan, B.H., Wigmore, S.J., et al.: The influence of systemic inflammation, dietary intake and stage of disease on rate of weight loss in patients with gastro-oesophageal cancer. Br. J. Cancer. (2009). https://doi.org/10.1038/sj.bjc.6604828</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Dülger</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Alici</ce:surname>
</author>
<author seq="3">
<ce:initials>M.R.</ce:initials>
<ce:surname>Şekeroǧlu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>Int. J. Clin. Pract</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1368-5031.2004.00149.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031.2004.00149.x</ref-fulltext>
<ce:source-text>Dülger, H., Alici, S., Şekeroǧlu, M.R., et al.: Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. Int. J. Clin. Pract. (2004). https://doi.org/10.1111/j.1368-5031.2004.00149.x</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Mantovani</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Macciò</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Madeddu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2001"/>
<ref-text>J. Mol. Med</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s001090100234</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/s001090100234</ref-fulltext>
<ce:source-text>Mantovani, G., Macciò, A., Madeddu, C., et al.: Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J. Mol. Med. (2001). https://doi.org/10.1007/s001090100234</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Staal-Van Cen Brekel</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Dentener</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.W.J.</ce:initials>
<ce:surname>Schols</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1995"/>
<ref-text>J. Clin. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.1995.13.10.2600</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Staal-van Cen Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13.10.2600</ref-fulltext>
<ce:source-text>Staal-van Cen Brekel, A.J., Dentener, M.A., Schols, A.M.W.J., et al.: Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. (1995). https://doi.org/10.1200/JCO.1995.13.10.2600</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Tas</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Duranyildiz</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Argon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Med. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1385/MO:22:4:353</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ref-fulltext>
<ce:source-text>Tas, F., Duranyildiz, D., Argon, A., et al.: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med. Oncol. (2005). https://doi.org/10.1385/MO:22:4:353</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: From tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Genes Dev</ref-text>
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. (2018)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>The immune contexture in human tumours: Impact on clinical outcome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.H.</ce:initials>
<ce:surname>Fridman</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pagès</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Sauts-Fridman</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Galon</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Nat. Rev. Cancer</ref-text>
</ref-info>
<ref-fulltext>Fridman, W.H., Pagès, F., Sauts-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ref-fulltext>
<ce:source-text>Fridman, W.H., Pagès, F., Sauts-Fridman, C., Galon, J.: The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. (2012)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Casneuf</ce:surname>
</author>
<author seq="2">
<ce:initials>A.E.</ce:initials>
<ce:surname>Axel</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>King</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Breast Cancer Targets Therapy</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.2147/BCTT.S92414</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https://doi.org/10.2147/BCTT.S92414</ref-fulltext>
<ce:source-text>Casneuf, T., Axel, A.E., King, P., et al.: Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer Targets Therapy. (2016). https://doi.org/10.2147/BCTT.S92414</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.W.</ce:initials>
<ce:surname>Edwardson</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Boudreau</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Mapletoft</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0183662</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi.org/10.1371/journal.pone.0183662</ref-fulltext>
<ce:source-text>Edwardson, D.W., Boudreau, J., Mapletoft, J., et al.: Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. (2017). https://doi.org/10.1371/journal.pone.0183662</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sprowl</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Reed</ce:surname>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Armstrong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Breast Cancer Res</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/bcr3083</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10.1186/bcr3083</ref-fulltext>
<ce:source-text>Sprowl, J.A., Reed, K., Armstrong, S.R., et al.: Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: A study in isogenic resistant tumor cells. Breast Cancer Res. (2012). https://doi.org/10.1186/bcr3083</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Frost</ce:surname>
</author>
<author seq="2">
<ce:initials>G.J.</ce:initials>
<ce:surname>Nystrom</ce:surname>
</author>
<author seq="3">
<ce:initials>L.S.</ce:initials>
<ce:surname>Jefferson</ce:surname>
</author>
<author seq="4">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lang</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Am. J. Physiol. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00359.2006</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C.H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ref-fulltext>
<ce:source-text>Frost, R.A., Nystrom, G.J., Jefferson, L.S., Lang, C.H.: Hormone, cytokine, and nutritional regulation of sepsis-induced increases in atrogin-1 and MuRF1 in skeletal muscle. Am. J. Physiol. Endocrinol. Metab. (2007). https://doi.org/10.1152/ajpendo.00359.2006</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.P.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>John</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.04-2364com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ref-fulltext>
<ce:source-text>Li, Y.P., Chen, Y., John, J., et al.: TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. (2005). https://doi.org/10.1096/fj.04-2364com</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Moylan</ce:surname>
</author>
<author seq="2">
<ce:initials>J.D.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.A.</ce:initials>
<ce:surname>Chambers</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Am. J. Physiol. Cell Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00041.2008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00041.2008</ref-fulltext>
<ce:source-text>Moylan, J.S., Smith, J.D., Chambers, M.A., et al.: TNF induction of atrogin-1/MAFbx mRNA depends on Foxo4 expression but not AKT-Foxo1/3 signaling. Am. J. Physiol. Cell Physiol. (2008). https://doi.org/10.1152/ajpcell.00041.2008</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.J.N.</ce:initials>
<ce:surname>Sishi</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Engelbrecht</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cytokine</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cyto.2011.01.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10.1016/j.cyto.2011.01.009</ref-fulltext>
<ce:source-text>Sishi, B.J.N., Engelbrecht, A.M.: Tumor necrosis factor alpha (TNF-α) inactivates the PI3-kinase/PKB pathway and induces atrophy and apoptosis in L6 myotubes. Cytokine. (2011). https://doi.org/10.1016/j.cyto.2011.01.009</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Tumors secreting human TNF/cachectin induce cachexia in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Oliff</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Defeo-Jones</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Boyer</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1987"/>
<ref-text>Cell</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0092-8674(87)90028-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092-8674(87)90028-6</ref-fulltext>
<ce:source-text>Oliff, A., Defeo-Jones, D., Boyer, M., et al.: Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. (1987). https://doi.org/10.1016/0092-8674(87)90028-6</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
<author seq="2">
<ce:initials>H.L.</ce:initials>
<ce:surname>Ritter</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Dueck</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Lung Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2009.06.020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j.lungcan.2009.06.020</ref-fulltext>
<ce:source-text>Jatoi, A., Ritter, H.L., Dueck, A., et al.: A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. (2010). https://doi.org/10.1016/j.lungcan.2009.06.020</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin-6 and cachexia in ApcMin/+ mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
</author>
<author seq="2">
<ce:initials>F.G.</ce:initials>
<ce:surname>Berger</ce:surname>
</author>
<author seq="3">
<ce:initials>M.M.O.</ce:initials>
<ce:surname>Pena</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00716.2007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ref-fulltext>
<ce:source-text>Baltgalvis, K.A., Berger, F.G., Pena, M.M.O., et al.: Interleukin-6 and cachexia in ApcMin/+ mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2008). https://doi.org/10.1152/ajpregu.00716.2007</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Interleukin 6 as a key regulator of muscle mass during cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Carson</ce:surname>
</author>
<author seq="2">
<ce:initials>K.A.</ce:initials>
<ce:surname>Baltgalvis</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Exerc. Sport Sci. Rev</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/JES.0b013e3181f44f11</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES.0b013e3181f44f11</ref-fulltext>
<ce:source-text>Carson, J.A., Baltgalvis, K.A.: Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. (2010). https://doi.org/10.1097/JES.0b013e3181f44f11</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: Relationship to acute phase response and survival</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Maingay</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Sangster</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Oncol. Rep</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or_00000328</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https://doi.org/10.3892/or_00000328</ref-fulltext>
<ce:source-text>Moses, A.G.W., Maingay, J., Sangster, K., et al.: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol. Rep. (2009). https://doi.org/10.3892/or_00000328</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>The relationship between weight loss and interleukin 6 in non-small-cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.R.</ce:initials>
<ce:surname>Scott</ce:surname>
</author>
<author seq="2">
<ce:initials>D.C.</ce:initials>
<ce:surname>McMillan</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Crilly</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>Br. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/bjc.1996.294</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ref-fulltext>
<ce:source-text>Scott, H.R., McMillan, D.C., Crilly, A., et al.: The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br. J. Cancer. (1996). https://doi.org/10.1038/bjc.1996.294</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways</ref-titletext-english>
</ref-title>
<itemidlist>
<ce:doi>10.1002/(SICI)1097-0215(19961127)68:5&lt;637::AID-IJC14&gt;3.0.CO;2-Z</ce:doi>
</itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fujlta</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Tsujinaka</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Yano</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>Int. J. Cancer</ref-text>
</ref-info>
<ref-fulltext>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:5&lt;637::AID-IJC14&gt;3.0.CO;2-Z</ref-fulltext>
<ce:source-text>Fujlta, J., Tsujinaka, T., Yano, M., et al.: Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int. J. Cancer. (1996). 10.1002/(SICI)1097-0215(19961127)68:5&lt;637::AID-IJC14&gt;3.0.CO;2-Z</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>White</ce:surname>
</author>
<author seq="2">
<ce:initials>J.W.</ce:initials>
<ce:surname>Baynes</ce:surname>
</author>
<author seq="3">
<ce:initials>S.L.</ce:initials>
<ce:surname>Welle</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0024650</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0024650</ref-fulltext>
<ce:source-text>White, J.P., Baynes, J.W., Welle, S.L., et al.: The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc Min/+ mouse. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0024650</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Bayliss</ce:surname>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Schuster</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Expert. Opin. Biol. Ther</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1517/14712598.2011.627850</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598.2011.627850</ref-fulltext>
<ce:source-text>Bayliss, T.J., Smith, J.T., Schuster, M., et al.: A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert. Opin. Biol. Ther. (2011). https://doi.org/10.1517/14712598.2011.627850</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Dogra</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Changotra</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Wedhas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-7537com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06-7537com</ref-fulltext>
<ce:source-text>Dogra, C., Changotra, H., Wedhas, N., et al.: TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. (2007). https://doi.org/10.1096/fj.06-7537com</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Mittal</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhatnagar</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J. Cell Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200909117</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/jcb.200909117</ref-fulltext>
<ce:source-text>Mittal, A., Bhatnagar, S., Kumar, A., et al.: The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. (2010). https://doi.org/10.1083/jcb.200909117</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 in skeletal muscle function and disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Guadagnin</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Mázala</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Int. J. Mol. Sci</ref-text>
</ref-info>
<ref-fulltext>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ref-fulltext>
<ce:source-text>Guadagnin, E., Mázala, D., Chen, Y.W.: STAT3 in skeletal muscle function and disorders. Int. J. Mol. Sci. (2018)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Sala</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Sacco</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Curr. Opin. Clin. Nutr. Metab. Care</ref-text>
</ref-info>
<ref-fulltext>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ref-fulltext>
<ce:source-text>Sala, D., Sacco, A.: Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases. Curr. Opin. Clin. Nutr. Metab. Care. (2016)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kunzevitzky</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0022538</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0022538</ref-fulltext>
<ce:source-text>Bonetto, A., Aydogdu, T., Kunzevitzky, N., et al.: STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. (2011). https://doi.org/10.1371/journal.pone.0022538</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Pan</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Cell Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2013.07.012</ce:e-address>
</ref-website>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https://doi.org/10.1016/j.cmet.2013.07.012</ref-fulltext>
<ce:source-text>Zhang, L., Pan, J., Dong, Y., et al.: Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. Cell Metab. (2013a). https://doi.org/10.1016/j.cmet.2013.07.012</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Allen</ce:surname>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>Cleary</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Hanson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.00247.2010</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ref-fulltext>
<ce:source-text>Allen, D.L., Cleary, A.S., Hanson, A.M., et al.: CCAAT/enhancer binding protein-δ expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2010). https://doi.org/10.1152/ajpregu.00247.2010</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-induced cachexia is Jak2-dependent in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gilabert</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Calvo</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Airoldi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>J. Cell. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.24580</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gilabert, M., Calvo, E., Airoldi, A., et al.: Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J. Cell. Physiol. (2014). https://doi.org/10.1002/jcp.24580</ref-fulltext>
<ce:source-text>Gilabert, M., Calvo, E., Airoldi, A., et al.: Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J. Cell. Physiol. (2014). https://doi.org/10.1002/jcp.24580</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.S.</ce:initials>
<ce:surname>Silva</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dong</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Dong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>J. Biol. Chem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M115.641514</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ref-fulltext>
<ce:source-text>Silva, K.A.S., Dong, J., Dong, Y., et al.: Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia. J. Biol. Chem. (2015). https://doi.org/10.1074/jbc.M115.641514</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2020"/>
<ref-text>Pharmacol. Res</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.phrs.2020.104871</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020.104871</ref-fulltext>
<ce:source-text>Chen, L., Xu, W., Yang, Q., et al.: Imperatorin alleviates cancer cachexia and prevents muscle wasting via directly inhibiting STAT3. Pharmacol. Res. (2020). https://doi.org/10.1016/j.phrs.2020.104871</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Cai</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Frantz</ce:surname>
</author>
<author seq="3">
<ce:initials>E.T.</ce:initials>
<ce:surname>Nicholas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>Cell</ref-text>
</ref-info>
<ref-fulltext>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ref-fulltext>
<ce:source-text>Cai, D., Frantz Jr., J., Nicholas Jr., E.T., et al.: IKK [beta]/NF-[kappa] B activation causes severe muscle wasting in mice. Cell. (2004)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Nf-kb and inflammatory cytokine signalling: Role in skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Thoma</ce:surname>
</author>
<author seq="2">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lightfoot</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Advances in Experimental Medicine and Biology</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ref-fulltext>
<ce:source-text>Thoma, A., Lightfoot, A.P.: Nf-kb and inflammatory cytokine signalling: role in skeletal muscle atrophy. In: Advances in experimental medicine and biology (2018)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ashall</ce:surname>
</author>
<author seq="2">
<ce:initials>C.A.</ce:initials>
<ce:surname>Horton</ce:surname>
</author>
<author seq="3">
<ce:initials>D.E.</ce:initials>
<ce:surname>Nelson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Science</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1164860</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ref-fulltext>
<ce:source-text>Ashall, L., Horton, C.A., Nelson, D.E., et al.: Pulsatile stimulation determines timing and specificity of NF-κB-dependent transcription. Science. (2009). https://doi.org/10.1126/science.1164860</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
<author seq="2">
<ce:initials>M.E.R.</ce:initials>
<ce:surname>Butchbach</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Sahenk</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Cancer Cell</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2005.10.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10.1016/j.ccr.2005.10.004</ref-fulltext>
<ce:source-text>Acharyya, S., Butchbach, M.E.R., Sahenk, Z., et al.: Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell. (2005). https://doi.org/10.1016/j.ccr.2005.10.004</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Rhoads</ce:surname>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Kandarian</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pacelli</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Eur. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ejca.2009.10.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ref-fulltext>
<ce:source-text>Rhoads, M.G., Kandarian, S.C., Pacelli, F., et al.: Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. (2010). https://doi.org/10.1016/j.ejca.2009.10.008</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Kawamura</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Morishita</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Tomita</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1999"/>
<ref-text>Gene Ther</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.gt.3300819</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10.1038/sj.gt.3300819</ref-fulltext>
<ce:source-text>Kawamura, I., Morishita, R., Tomita, N., et al.: Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. (1999). https://doi.org/10.1038/sj.gt.3300819</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>Grossberg</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Krasnow</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.13-230375</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj.13-230375</ref-fulltext>
<ce:source-text>Braun, T.P., Grossberg, A.J., Krasnow, S.M., et al.: Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J. (2013). https://doi.org/10.1096/fj.13-230375</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Neurobiology of inflammation-associated anorexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Gautron</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Front. Neurosci</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/neuro.23.003.2009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gautron, L.: Neurobiology of inflammation-associated anorexia. Front. Neurosci. (2009). https://doi.org/10.3389/neuro.23.003.2009</ref-fulltext>
<ce:source-text>Gautron, L.: Neurobiology of inflammation-associated anorexia. Front. Neurosci. (2009). https://doi.org/10.3389/neuro.23.003.2009</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cole</ce:surname>
</author>
<author seq="2">
<ce:initials>I.R.</ce:initials>
<ce:surname>Kleckner</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jatoi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>JCSM Clin. Reports</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.17987/jcsm-cr.v3i2.65</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https://doi.org/10.17987/jcsm-cr.v3i2.65</ref-fulltext>
<ce:source-text>Cole, C.L., Kleckner, I.R., Jatoi, A., et al.: The role of systemic inflammation in cancer-associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin. Reports. (2018). https://doi.org/10.17987/jcsm-cr.v3i2.65</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Fuller</ce:surname>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Hartland</ce:surname>
</author>
<author seq="3">
<ce:initials>L.T.</ce:initials>
<ce:surname>Maloney</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Davison</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Br. J. Sports Med</ref-text>
</ref-info>
<ref-fulltext>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ref-fulltext>
<ce:source-text>Fuller, J.T., Hartland, M.C., Maloney, L.T., Davison, K.: Therapeutic effects of aerobic and resistance exercises for cancer survivors: A systematic review of meta-analyses of clinical trials. Br. J. Sports Med. (2018)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Lønbro</ce:surname>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Dalgas</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Primdahl</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Radiother. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.radonc.2013.07.002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial. Radiother. Oncol. (2013). https://doi.org/10.1016/j.radonc.2013.07.002</ref-fulltext>
<ce:source-text>Lønbro, S., Dalgas, U., Primdahl, H., et al.: Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy – results from the randomized DAHANCA 25B trial. Radiother. Oncol. (2013). https://doi.org/10.1016/j.radonc.2013.07.002</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise interventions on health-related quality of life for cancer survivors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.I.</ce:initials>
<ce:surname>Mishra</ce:surname>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Scherer</ce:surname>
</author>
<author seq="3">
<ce:initials>P.M.</ce:initials>
<ce:surname>Geigle</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Cochrane Database Syst. Rev</ref-text>
</ref-info>
<ref-fulltext>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ref-fulltext>
<ce:source-text>Mishra, S.I., Scherer, R.W., Geigle, P.M., et al.: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst. Rev. (2012)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.B.</ce:initials>
<ce:surname>Nadler</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Desnoyers</ce:surname>
</author>
<author seq="3">
<ce:initials>D.M.</ce:initials>
<ce:surname>Langelier</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Amir</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J. Pain Sympt. Manag</ref-text>
</ref-info>
<ref-fulltext>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ref-fulltext>
<ce:source-text>Nadler, M.B., Desnoyers, A., Langelier, D.M., Amir, E.: The effect of exercise on quality of life, fatigue, physical function, and safety in advanced solid tumor cancers: A meta-analysis of randomized control trials. J. Pain Sympt. Manag. (2019)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Physical exercise for cancer patients with advanced disease: A randomized controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.M.</ce:initials>
<ce:surname>Oldervoll</ce:surname>
</author>
<author seq="2">
<ce:initials>J.H.</ce:initials>
<ce:surname>Loge</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lydersen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Oncologist</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1634/theoncologist.2011-0133</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: A randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist.2011-0133</ref-fulltext>
<ce:source-text>Oldervoll, L.M., Loge, J.H., Lydersen, S., et al.: Physical exercise for cancer patients with advanced disease: A randomized controlled trial. Oncologist. (2011). https://doi.org/10.1634/theoncologist.2011-0133</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise training as therapy for cardiac and cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.R.R.</ce:initials>
<ce:surname>Alves</ce:surname>
</author>
<author seq="2">
<ce:initials>T.F.</ce:initials>
<ce:surname>da Cunha</ce:surname>
</author>
<author seq="3">
<ce:initials>N.A.</ce:initials>
<ce:surname>da Paixão</ce:surname>
</author>
<author seq="4">
<ce:initials>P.C.</ce:initials>
<ce:surname>Brum</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Life Sci</ref-text>
</ref-info>
<ref-fulltext>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ref-fulltext>
<ce:source-text>Alves, C.R.R., Da Cunha, T.F., Da Paixão, N.A., Brum, P.C.: Aerobic exercise training as therapy for cardiac and cancer cachexia. Life Sci. (2015)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tanaka</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Sugimoto</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Fujimoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.201802430R</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ref-fulltext>
<ce:source-text>Tanaka, M., Sugimoto, K., Fujimoto, T., et al.: Preventive effects of low-intensity exercise on cancer cachexia-induced muscle atrophy. FASEB J. (2019). https://doi.org/10.1096/fj.201802430R</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Gleeson</ce:surname>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Bishop</ce:surname>
</author>
<author seq="3">
<ce:initials>D.J.</ce:initials>
<ce:surname>Stensel</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Nat. Rev. Immunol</ref-text>
</ref-info>
<ref-fulltext>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ref-fulltext>
<ce:source-text>Gleeson, M., Bishop, N.C., Stensel, D.J., et al.: The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. (2011)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Kasapis</ce:surname>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>J. Am. Coll. Cardiol</ref-text>
</ref-info>
<ref-fulltext>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J. Am. Coll. Cardiol. (2005)</ref-fulltext>
<ce:source-text>Kasapis, C., Thompson, P.D.: The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J. Am. Coll. Cardiol. (2005)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory effect of exercise</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.W.</ce:initials>
<ce:surname>Petersen</ce:surname>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Pedersen</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>J. Appl. Physiol</ref-text>
</ref-info>
<ref-fulltext>Petersen, A.M.W., Pedersen, B.K.: The anti-inflammatory effect of exercise. J. Appl. Physiol. (2005)</ref-fulltext>
<ce:source-text>Petersen, A.M.W., Pedersen, B.K.: The anti-inflammatory effect of exercise. J. Appl. Physiol. (2005)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>The discovery of TGF-β: A historical perspective</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.L.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>The TGF-β Family</ref-text>
</ref-info>
<ref-fulltext>Moses, H.L.: The discovery of TGF-β: A historical perspective. In: The TGF-β Family (2008)</ref-fulltext>
<ce:source-text>Moses, H.L.: The discovery of TGF-β: A historical perspective. In: The TGF-β Family (2008)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β signaling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Syed</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>J. Cell. Biochem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcb.25496</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ref-fulltext>
<ce:source-text>Syed, V.: TGF-β signaling in cancer. J. Cell. Biochem. (2016). https://doi.org/10.1002/jcb.25496</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting the myostatin signaling pathway to treat muscle wasting diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Curr. Opin. Support. Palliative Care</ref-text>
</ref-info>
<ref-fulltext>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ref-fulltext>
<ce:source-text>Han, H.Q., Mitch, W.E.: Targeting the myostatin signaling pathway to treat muscle wasting diseases. Curr. Opin. Support. Palliative Care. (2011)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.Q.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="3">
<ce:initials>W.E.</ce:initials>
<ce:surname>Mitch</ce:surname>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Int. J. Biochem. Cell Biol</ref-text>
</ref-info>
<ref-fulltext>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Han, H.Q., Zhou, X., Mitch, W.E., Goldberg, A.L.: Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Target genes of myostatin loss-of-function in muscles of late bovine fetuses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Cassar-Malek</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Passelaigue</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Bernard</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>BMC Genomics</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2164-8-63</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ref-fulltext>
<ce:source-text>Cassar-Malek, I., Passelaigue, F., Bernard, C., et al.: Target genes of myostatin loss-of-function in muscles of late bovine fetuses. BMC Genomics. (2007). https://doi.org/10.1186/1471-2164-8-63</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Clop</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Marcq</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Takeda</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>Nat. Genet</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/ng1810</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clop, A., Marcq, F., Takeda, H., et al.: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. (2006). https://doi.org/10.1038/ng1810</ref-fulltext>
<ce:source-text>Clop, A., Marcq, F., Takeda, H., et al.: A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. (2006). https://doi.org/10.1038/ng1810</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>McPherron</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Lawler</ce:surname>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/387083a0</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/10.1038/387083a0</ref-fulltext>
<ce:source-text>McPherron, A.C., Lawler, A.M., Lee, S.J.: Regulation of skeletal muscle mass in mice by a new TGF-β superfamily member. Nature. (1997). https://doi.org/10.1038/387083a0</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Mosher</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Quignon</ce:surname>
</author>
<author seq="3">
<ce:initials>C.D.</ce:initials>
<ce:surname>Bustamante</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Plos Genet</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pgen.0030079</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. (2007). https://doi.org/10.1371/journal.pgen.0030079</ref-fulltext>
<ce:source-text>Mosher, D.S., Quignon, P., Bustamante, C.D., et al.: A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. (2007). https://doi.org/10.1371/journal.pgen.0030079</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin mutation associated with gross muscle hypertrophy in a child</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Schuelke</ce:surname>
</author>
<author seq="2">
<ce:initials>K.R.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<author seq="3">
<ce:initials>L.E.</ce:initials>
<ce:surname>Stolz</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>N. Engl. J. Med</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1056/NEJMoa040933</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ref-fulltext>
<ce:source-text>Schuelke, M., Wagner, K.R., Stolz, L.E., et al.: Myostatin mutation associated with gross muscle hypertrophy in a child. N. Engl. J. Med. (2004). https://doi.org/10.1056/NEJMoa040933</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Durieux</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Amirouche</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Banzet</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Endocrinology</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/en.2006-1500</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/10.1210/en.2006-1500</ref-fulltext>
<ce:source-text>Durieux, A.C., Amirouche, A., Banzet, S., et al.: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. (2007). https://doi.org/10.1210/en.2006-1500</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of cachexia in mice by systemically administered myostatin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:surname>Zimmers</ce:surname>
</author>
<author seq="2">
<ce:initials>M.V.</ce:initials>
<ce:surname>Davies</ce:surname>
</author>
<author seq="3">
<ce:initials>L.G.</ce:initials>
<ce:surname>Koniaris</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>Science</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>296</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1486</first-page>
<last-page>1488</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1069525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ref-fulltext>
<ce:source-text>Zimmers, T.A., Davies, M.V., Koniaris, L.G., et al.: Induction of cachexia in mice by systemically administered myostatin. Science. 296, 1486–1488 (2002). https://doi.org/10.1126/science.1069525</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin from the heart: Local and systemic actions in cardiac failure and muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbart</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Auger-Messier</ce:surname>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Molkentin</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Heineke</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Am. J. Physiol. Heart Circ. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpheart.00200.2011</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https://doi.org/10.1152/ajpheart.00200.2011</ref-fulltext>
<ce:source-text>Breitbart, A., Auger-Messier, M., Molkentin, J.D., Heineke, J.: Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Heart Circ. Physiol. (2011). https://doi.org/10.1152/ajpheart.00200.2011</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Breitbart</ce:surname>
</author>
<author seq="2">
<ce:initials>G.M.</ce:initials>
<ce:surname>Scharf</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Duncker</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0080454</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone.0080454</ref-fulltext>
<ce:source-text>Breitbart, A., Scharf, G.M., Duncker, D., et al.: Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One. (2013). https://doi.org/10.1371/journal.pone.0080454</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.F.</ce:initials>
<ce:surname>Gonzalez-Cadavid</ce:surname>
</author>
<author seq="2">
<ce:initials>W.E.</ce:initials>
<ce:surname>Taylor</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1998"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.95.25.14938</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ref-fulltext>
<ce:source-text>Gonzalez-Cadavid, N.F., Taylor, W.E., Yarasheski, K., et al.: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. USA. (1998). https://doi.org/10.1073/pnas.95.25.14938</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Role of activin A and myostatin in human cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Loumaye</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>de Barsy</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Nachit</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>J. Clin. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jc.2014-4318</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https://doi.org/10.1210/jc.2014-4318</ref-fulltext>
<ce:source-text>Loumaye, A., De Barsy, M., Nachit, M., et al.: Role of activin A and myostatin in human cancer cachexia. J. Clin. Endocrinol. Metab. (2015). https://doi.org/10.1210/jc.2014-4318</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.E.</ce:initials>
<ce:surname>Yarasheski</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Sinha-Hikim</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>J. Nutr. Health Aging</ref-text>
</ref-info>
<ref-fulltext>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ref-fulltext>
<ce:source-text>Yarasheski, K.E., Bhasin, S., Sinha-Hikim, I., et al.: Serum myostatin-immunoreactive protein is increased in 60–92 year old women and men with muscle wasting. J. Nutr. Health Aging. (2002)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.M.</ce:initials>
<ce:surname>de Kretser</ce:surname>
</author>
<author seq="2">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
</author>
<author seq="3">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
</author>
<author seq="4">
<ce:initials>M.P.</ce:initials>
<ce:surname>Hedger</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Mol. Cell. Endocrinol</ref-text>
</ref-info>
<ref-fulltext>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ref-fulltext>
<ce:source-text>de Kretser, D.M., O’Hehir, R.E., Hardy, C.L., Hedger, M.P.: The roles of activin A and its binding protein, follistatin, in inflammation and tissue repair. Mol. Cell. Endocrinol. (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>The immunoregulatory and fibrotic roles of activin A in allergic asthma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Hardy</ce:surname>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rolland</ce:surname>
</author>
<author seq="3">
<ce:initials>R.E.</ce:initials>
<ce:surname>O’Hehir</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Clin. Exp. Allergy</ref-text>
</ref-info>
<ref-fulltext>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ref-fulltext>
<ce:source-text>Hardy, C.L., Rolland, J.M., O’Hehir, R.E.: The immunoregulatory and fibrotic roles of activin A in allergic asthma. Clin. Exp. Allergy. (2015)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Mansell</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Patella</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0705971104</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ref-fulltext>
<ce:source-text>Jones, K.L., Mansell, A., Patella, S., et al.: Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia. Proc. Natl. Acad. Sci. USA. (2007). https://doi.org/10.1073/pnas.0705971104</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Dankbar</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Fennen</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Brunert</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat. Med</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nm.3917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/10.1038/nm.3917</ref-fulltext>
<ce:source-text>Dankbar, B., Fennen, M., Brunert, D., et al.: Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat. Med. (2015). https://doi.org/10.1038/nm.3917</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Rajan</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.10-176917</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https://doi.org/10.1096/fj.10-176917</ref-fulltext>
<ce:source-text>Zhang, L., Rajan, V., Lin, E., et al.: Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J. (2011). https://doi.org/10.1096/fj.10-176917</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Changes in myostatin signaling in non-weight-losing cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Ann. Surg. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1245/s10434-011-1720-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/10.1245/s10434-011-1720-5</ref-fulltext>
<ce:source-text>Aversa, Z., Bonetto, A., Penna, F., et al.: Changes in myostatin signaling in non-weight-losing cancer patients. Ann. Surg. Oncol. (2012). https://doi.org/10.1245/s10434-011-1720-5</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Serum immunoreactive activin A levels in normal subjects and patients with various diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Harada</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shintani</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Sakamoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>J. Clin. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/jc.81.6.2125</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/jc.81.6.2125</ref-fulltext>
<ce:source-text>Harada, K., Shintani, Y., Sakamoto, Y., et al.: Serum immunoreactive activin A levels in normal subjects and patients with various diseases. J. Clin. Endocrinol. Metab. (1996). https://doi.org/10.1210/jc.81.6.2125</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Rini</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Anticancer Res</ref-text>
</ref-info>
<ref-fulltext>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. (2007)</ref-fulltext>
<ce:source-text>Incorvaia, L., Badalamenti, G., Rini, G., et al.: MMP-2, MMP-9 and activin a blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res. (2007)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Activin A circulating levels in patients with bone metastasis from breast or prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Leto</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Incorvaia</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Badalamenti</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>Clin. Exp. Metastasis</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s10585-006-9010-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585-006-9010-5</ref-fulltext>
<ce:source-text>Leto, G., Incorvaia, L., Badalamenti, G., et al.: Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin. Exp. Metastasis. (2006). https://doi.org/10.1007/s10585-006-9010-5</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle myostatin signalling is enhanced in experimental cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Eur. J. Clin. Investig</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1365-2362.2008.01970.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https://doi.org/10.1111/j.1365-2362.2008.01970.x</ref-fulltext>
<ce:source-text>Costelli, P., Muscaritoli, M., Bonetto, A., et al.: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. (2008). https://doi.org/10.1111/j.1365-2362.2008.01970.x</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Aydogdu</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Link</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Biochem. Biophys. Res. Commun</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.bbrc.2009.12.123</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., Aydogdu, T., Link, M.J., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. (2010). https://doi.org/10.1016/j.bbrc.2009.12.123</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Barreto</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitase</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Matsumoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Sci. Rep</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-15040-1</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ref-fulltext>
<ce:source-text>Barreto, R., Kitase, Y., Matsumoto, T., et al.: ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-15040-1</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.M.</ce:initials>
<ce:surname>O’Connell</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="3">
<ce:initials>M.E.</ce:initials>
<ce:surname>Couch</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/cancers11091222</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/cancers11091222</ref-fulltext>
<ce:source-text>O’Connell, T.M., Pin, F., Couch, M.E., Bonetto, A.: Treatment with soluble activin receptor type IIB alters metabolic response in chemotherapy-induced cachexia. Cancers. (2019). https://doi.org/10.3390/cancers11091222</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Greco</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tomkötter</ce:surname>
</author>
<author seq="3">
<ce:initials>A.K.</ce:initials>
<ce:surname>Vahle</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0132786</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/10.1371/journal.pone.0132786</ref-fulltext>
<ce:source-text>Greco, S.H., Tomkötter, L., Vahle, A.K., et al.: TGF-β blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia. PLoS One. (2015). https://doi.org/10.1371/journal.pone.0132786</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="2">
<ce:initials>B.K.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Curr. Opin. Support. Palliative Care</ref-text>
</ref-info>
<ref-fulltext>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ref-fulltext>
<ce:source-text>Smith, R.C., Lin, B.K.: Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr. Opin. Support. Palliative Care. (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.S.</ce:initials>
<ce:surname>Jameson</ce:surname>
</author>
<author seq="2">
<ce:initials>D.D.</ce:initials>
<ce:surname>von Hoff</ce:surname>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Weiss</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>J. Clin. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ref-fulltext>
<ce:source-text>Jameson, G.S., Von Hoff, D.D., Weiss, G.J., et al.: Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer. J. Clin. Oncol. (2012). https://doi.org/10.1200/jco.2012.30.15_suppl.2516</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular therapeutic strategies targeting pancreatic cancer induced cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Yakovenko</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cameron</ce:surname>
</author>
<author seq="3">
<ce:initials>J.G.</ce:initials>
<ce:surname>Trevino</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>World J. Gastroint. Surg</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4240/wjgs.v10.i9.95</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95</ref-fulltext>
<ce:source-text>Yakovenko, A., Cameron, M., Trevino, J.G.: Molecular therapeutic strategies targeting pancreatic cancer induced cachexia. World J. Gastroint. Surg. (2018). https://doi.org/10.4240/wjgs.v10.i9.95</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Dieli-Conwright</ce:surname>
</author>
<author seq="2">
<ce:initials>T.M.</ce:initials>
<ce:surname>Spektor</ce:surname>
</author>
<author seq="3">
<ce:initials>J.C.</ce:initials>
<ce:surname>Rice</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>J. Strength Cond. Res</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1519/JSC.0b013e318251083f</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC.0b013e318251083f</ref-fulltext>
<ce:source-text>Dieli-Conwright, C.M., Spektor, T.M., Rice, J.C., et al.: Hormone therapy and maximal eccentric exercise alters myostatin-related gene expression in postmenopausal women. J. Strength Cond. Res. (2012). https://doi.org/10.1519/JSC.0b013e318251083f</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Matsakas</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Friedel</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Hertrampf</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Diel</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Acta Physiol. Scand</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ref-fulltext>
<ce:source-text>Matsakas, A., Friedel, A., Hertrampf, T., Diel, P.: Short-term endurance training results in a muscle-specific decrease of myostatin mRNA content in the rat. Acta Physiol. Scand. (2005). https://doi.org/10.1111/j.1365-201X.2005.01406.x</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Bassi</ce:surname>
</author>
<author seq="2">
<ce:initials>P.D.G.</ce:initials>
<ce:surname>Bueno</ce:surname>
</author>
<author seq="3">
<ce:initials>K.O.</ce:initials>
<ce:surname>Nonaka</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Arch. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1590/2359-3997000000028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ref-fulltext>
<ce:source-text>Bassi, D., Bueno, P.d.G., Nonaka, K.O., et al.: Exercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats. Arch. Endocrinol. Metab. (2015). https://doi.org/10.1590/2359-3997000000028</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin decreases with aerobic exercise and associates with insulin resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Hittel</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Axelson</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sarna</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Med. Sci. Sports Exerc</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ref-fulltext>
<ce:source-text>Hittel, D.S., Axelson, M., Sarna, N., et al.: Myostatin decreases with aerobic exercise and associates with insulin resistance. Med. Sci. Sports Exerc. (2010). https://doi.org/10.1249/MSS.0b013e3181e0b9a8</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Kopple</ce:surname>
</author>
<author seq="2">
<ce:initials>A.H.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>J. Ren. Nutr</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1053/j.jrn.2006.04.028</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ref-fulltext>
<ce:source-text>Kopple, J.D., Cohen, A.H., Wang, H., et al.: Effect of exercise on mRNA levels for growth factors in skeletal muscle of hemodialysis patients. J. Ren. Nutr. (2006). https://doi.org/10.1053/j.jrn.2006.04.028</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Lenk</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Schur</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Linke</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Eur. J. Heart Fail</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hfp020</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ref-fulltext>
<ce:source-text>Lenk, K., Schur, R., Linke, A., et al.: Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail. (2009). https://doi.org/10.1093/eurjhf/hfp020</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular adaptations to aerobic exercise training in skeletal muscle of older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Konopka</ce:surname>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Douglass</ce:surname>
</author>
<author seq="3">
<ce:initials>L.A.</ce:initials>
<ce:surname>Kaminsky</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J. Gerontol. Ser a Biol. Sci. Med. Sci</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/gerona/glq109</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ref-fulltext>
<ce:source-text>Konopka, A.R., Douglass, M.D., Kaminsky, L.A., et al.: Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser A Biol. Sci. Med. Sci. (2010). https://doi.org/10.1093/gerona/glq109</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Ryan</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Blumenthal</ce:surname>
</author>
<author seq="4">
<ce:initials>H.K.</ce:initials>
<ce:surname>Ortmeyer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Obesity</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20216</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ref-fulltext>
<ce:source-text>Ryan, A.S., Li, G., Blumenthal, J.B., Ortmeyer, H.K.: Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults. Obesity. (2013). https://doi.org/10.1002/oby.20216</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.E.</ce:initials>
<ce:surname>Coutinho</ce:surname>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>Chapman</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Mol. Cell. Endocrinol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>13</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.mce.2010.04.005</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ref-fulltext>
<ce:source-text>Coutinho, A.E., Chapman, K.E.: The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell. Endocrinol. 335, 2–13 (2011). https://doi.org/10.1016/j.mce.2010.04.005</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tanaka</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Eda</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Tanaka</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1990"/>
<ref-text>Cancer Res</ref-text>
</ref-info>
<ref-fulltext>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ref-fulltext>
<ce:source-text>Tanaka, Y., Eda, H., Tanaka, T., et al.: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. (1990)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Fagan</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Roegner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1996"/>
<ref-text>J. Clin. Investig</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI118421</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ref-fulltext>
<ce:source-text>Tiao, G., Fagan, J., Roegner, V., et al.: Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids. J. Clin. Investig. (1996). https://doi.org/10.1172/JCI118421</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.P.</ce:initials>
<ce:surname>Braun</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Szumowski</ce:surname>
</author>
<author seq="3">
<ce:initials>P.R.</ce:initials>
<ce:surname>Levasseur</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0106489</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ref-fulltext>
<ce:source-text>Braun, T.P., Szumowski, M., Levasseur, P.R., et al.: Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle. PLoS One. (2014). https://doi.org/10.1371/journal.pone.0106489</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Schakman</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Kalista</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Barbé</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Int. J. Biochem. Cell Biol</ref-text>
</ref-info>
<ref-fulltext>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ref-fulltext>
<ce:source-text>Schakman, O., Kalista, S., Barbé, C., et al.: Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. (2013)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of gluconeogenesis by glucocorticoids</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Exton</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1979"/>
<ref-text>Monogr. Endocrinol</ref-text>
</ref-info>
<ref-fulltext>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ref-fulltext>
<ce:source-text>Exton, J.H.: Regulation of gluconeogenesis by glucocorticoids. Monogr. Endocrinol. (1979)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Morgan</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sherlock</ce:surname>
</author>
<author seq="3">
<ce:initials>L.L.</ce:initials>
<ce:surname>Gathercole</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Diabetes</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.2337/db09-0525</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ref-fulltext>
<ce:source-text>Morgan, S.A., Sherlock, M., Gathercole, L.L., et al.: 11β-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes. (2009). https://doi.org/10.2337/db09-0525</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Nakao</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Hirasaka</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Goto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Mol. Cell. Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1128/mcb.01347-08</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ref-fulltext>
<ce:source-text>Nakao, R., Hirasaka, K., Goto, J., et al.: Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. (2009). https://doi.org/10.1128/mcb.01347-08</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ohkawa</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>FASEB J</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.09-151480</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ref-fulltext>
<ce:source-text>Zheng, B., Ohkawa, S., Li, H., et al.: FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB J. (2010). https://doi.org/10.1096/fj.09-151480</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Giorgino</ce:surname>
</author>
<author seq="2">
<ce:initials>M.T.</ce:initials>
<ce:surname>Pedrini</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Matera</ce:surname>
</author>
<author seq="4">
<ce:initials>R.J.</ce:initials>
<ce:surname>Smithi</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1997"/>
<ref-text>J. Biol. Chem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.272.11.7455</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ref-fulltext>
<ce:source-text>Giorgino, F., Pedrini, M.T., Matera, L., Smithi, R.J.: Specific increase in p85α expression in response to dexamethasone is associated with inhibition of insulin-like growth factor-I stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J. Biol. Chem. (1997). https://doi.org/10.1074/jbc.272.11.7455</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="3">
<ce:initials>H.L.</ce:initials>
<ce:surname>In</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>J. Clin. Investig</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI38770</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ref-fulltext>
<ce:source-text>Hu, Z., Wang, H., In, H.L., et al.: Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Investig. (2009). https://doi.org/10.1172/JCI38770</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Kuo</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Lew</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Mayba</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1111334109</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ref-fulltext>
<ce:source-text>Kuo, T., Lew, M.J., Mayba, O., et al.: Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc. Natl. Acad. Sci. USA. (2012). https://doi.org/10.1073/pnas.1111334109</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Artaza</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>J. Cell. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.10044</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https://doi.org/10.1002/jcp.10044</ref-fulltext>
<ce:source-text>Artaza, J.N., Bhasin, S., Mallidis, C., et al.: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J. Cell. Physiol. (2002). https://doi.org/10.1002/jcp.10044</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Mallidis</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Bhasin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2003"/>
<ref-text>Am. J. Physiol. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.00487.2002</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ref-fulltext>
<ce:source-text>Ma, K., Mallidis, C., Bhasin, S., et al.: Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am. J. Physiol. Endocrinol. Metab. (2003). https://doi.org/10.1152/ajpendo.00487.2002</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>McFarlane</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Plummer</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>J. Cell. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcp.20757</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ref-fulltext>
<ce:source-text>McFarlane, C., Plummer, E., Thomas, M., et al.: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. (2006). https://doi.org/10.1002/jcp.20757</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Cersosimo</ce:surname>
</author>
<author seq="2">
<ce:initials>P.W.T.</ce:initials>
<ce:surname>Pisters</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pesola</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1991"/>
<ref-text>Surgery</ref-text>
</ref-info>
<ref-fulltext>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ref-fulltext>
<ce:source-text>Cersosimo, E., Pisters, P.W.T., Pesola, G., et al.: The effect of graded doses of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery. (1991)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>Dodesini</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Benedini</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Terruzzi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Acta Oncol</ref-text>
</ref-info>
<ref-fulltext>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]. Acta Oncol. (2007)</ref-fulltext>
<ce:source-text>Dodesini, A.R., Benedini, S., Terruzzi, I., et al.: Protein, glucose and lipid metabolism in the cancer cachexia: A preliminary report [1]. Acta Oncol. (2007)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Diabetes and altered carbohydrate metabolism in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.S.</ce:initials>
<ce:surname>Glicksman</ce:surname>
</author>
<author seq="2">
<ce:initials>R.W.</ce:initials>
<ce:surname>Rawson</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1956"/>
<ref-text>Cancer</ref-text>
<ref-text>10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ref-text>
</ref-info>
<ref-fulltext>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ref-fulltext>
<ce:source-text>Glicksman, A.S., Rawson, R.W.: Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer. (1956) 10.1002/1097-0142(195611/12)9:6&lt;1127::AID-CNCR2820090610&gt;3.0.CO;2-4</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Sugar tolerance in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.L.</ce:initials>
<ce:surname>Rohdenburg</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bernhard</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Krehbiel</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1919"/>
<ref-text>J. Am. Med. Assoc</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1001/jama.1919.02610210024007</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ref-fulltext>
<ce:source-text>Rohdenburg, G.L., Bernhard, A., Krehbiel, O.: Sugar tolerance in cancer. J. Am. Med. Assoc. (1919). https://doi.org/10.1001/jama.1919.02610210024007</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>A review of cancer cachexia and abnormal glucose metabolism in humans with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Tayek</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1992"/>
<ref-text>J. Am. Coll. Nutr</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1080/07315724.1992.10718249</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10.1080/07315724.1992.10718249</ref-fulltext>
<ce:source-text>Tayek, J.A.: A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J. Am. Coll. Nutr. (1992). https://doi.org/10.1080/07315724.1992.10718249</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.L.</ce:initials>
<ce:surname>Asp</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Wendel</ce:surname>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Belury</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Int. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/ijc.24784</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ref-fulltext>
<ce:source-text>Asp, M.L., Tian, M., Wendel, A.A., Belury, M.A.: Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int. J. Cancer. (2010). https://doi.org/10.1002/ijc.24784</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Cachexia: A problem of energetic inefficiency</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Argilés</ce:surname>
</author>
<author seq="2">
<ce:initials>C.C.</ce:initials>
<ce:surname>Fontes-Oliveira</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Toledo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>J. Cachexia Sarcopenia Muscle</ref-text>
</ref-info>
<ref-fulltext>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ref-fulltext>
<ce:source-text>Argilés, J.M., Fontes-Oliveira, C.C., Toledo, M., et al.: Cachexia: A problem of energetic inefficiency. J. Cachexia Sarcopenia Muscle. (2014)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated energy expenditure in cancer patients with solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hyltander</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Drott</ce:surname>
</author>
<author seq="3">
<ce:initials>U.</ce:initials>
<ce:surname>Körner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1991"/>
<ref-text>Eur. J. Cancer Clin. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/0277-5379(91)90050-N</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ref-fulltext>
<ce:source-text>Hyltander, A., Drott, C., Körner, U., et al.: Elevated energy expenditure in cancer patients with solid tumours. Eur. J. Cancer Clin. Oncol. (1991). https://doi.org/10.1016/0277-5379(91)90050-N</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia, mechanism and treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Aoyagi</ce:surname>
</author>
<author seq="2">
<ce:initials>K.P.</ce:initials>
<ce:surname>Terracina</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raza</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>World J. Gastrointest. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4251/wjgo.v7.i4.17</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ref-fulltext>
<ce:source-text>Aoyagi, T., Terracina, K.P., Raza, A., et al.: Cancer cachexia, mechanism and treatment. World J. Gastrointest. Oncol. (2015). https://doi.org/10.4251/wjgo.v7.i4.17</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Faber</ce:surname>
</author>
<author seq="2">
<ce:initials>M.J.</ce:initials>
<ce:surname>Uitdehaag</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Spaander</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ref-fulltext>
<ce:source-text>Faber, J., Uitdehaag, M.J., Spaander, M., et al.: Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J. Cachexia. Sarcopenia Muscle. (2015). https://doi.org/10.1002/jcsm.12009</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Leśniak</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Bała</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Jaeschke</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Krzakowski</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Polskie Archiwum Medycyny Wewnetrznej</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.20452/pamw.510</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ref-fulltext>
<ce:source-text>Leśniak, W., Bała, M., Jaeschke, R., Krzakowski, M.: Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome – a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej. (2008). https://doi.org/10.20452/pamw.510</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.P.</ce:initials>
<ce:surname>López</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Roqué I Figuls</ce:surname>
</author>
<author seq="3">
<ce:initials>G.U.</ce:initials>
<ce:surname>Cuchi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>J. Pain Sympt. Manag</ref-text>
</ref-info>
<ref-fulltext>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ref-fulltext>
<ce:source-text>López AP, Roqué I Figuls M, Cuchi GU, et al (2004) Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J. Pain Sympt. Manag.</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Megestrol acetate for treatment of anorexia-cachexia syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Ruiz Garcia</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>López-Briz</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Carbonell Sanchis</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Cochrane Database Syst. Rev</ref-text>
</ref-info>
<ref-fulltext>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ref-fulltext>
<ce:source-text>Ruiz Garcia, V., López-Briz, E., Carbonell Sanchis, R., et al.: Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. (2013)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Systematic review of the treatment of cancer-associated anorexia and weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tugba</ce:surname>
</author>
<author seq="2">
<ce:initials>M.P.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Declan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>J. Clin. Oncol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8500</first-page>
<last-page>8511</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ref-fulltext>
<ce:source-text>Tugba, Y., Davis, M.P., Declan, W., et al.: Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23(33), 8500–8511 (2005)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Progesterone therapy for the treatment of non-cancer cachexia: A systematic review</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.K.</ce:initials>
<ce:surname>Taylor</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Pendleton</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>BMJ Support. Palliative Care</ref-text>
</ref-info>
<ref-fulltext>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ref-fulltext>
<ce:source-text>Taylor, J.K., Pendleton, N.: Progesterone therapy for the treatment of non-cancer cachexia: A systematic review. BMJ Support. Palliative Care. (2016)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lecker</ce:surname>
</author>
<author seq="2">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Gilbert</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>FASEB J</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>39</first-page>
<last-page>51</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.03-0610com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ref-fulltext>
<ce:source-text>Lecker, S.H., Jagoe, R.T., Gilbert, A., et al.: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18, 39–51 (2004). https://doi.org/10.1096/fj.03-0610com</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Sacheck</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Hyatt</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>FASEB J</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>140</first-page>
<last-page>155</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1096/fj.06-6604com</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ref-fulltext>
<ce:source-text>Sacheck, J.M., Hyatt, J.P., Raffaello, A., et al.: Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21, 140–155 (2007). https://doi.org/10.1096/fj.06-6604com</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 controls autophagy in skeletal muscle in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Mammucari</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Romanello</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Cell Metab</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>458</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ref-fulltext>
<ce:source-text>Mammucari, C., Milan, G., Romanello, V., et al.: FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 6, 458–471 (2007)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation and involvement of the ubiquitin ligases in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Free Radic. Biol. Med</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ref-fulltext>
<ce:source-text>Sandri, M.: Regulation and involvement of the ubiquitin ligases in muscle atrophy. Free Radic. Biol. Med. (2014). https://doi.org/10.1016/j.freeradbiomed.2014.10.833</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Schild</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Cell Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2007.11.004</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ref-fulltext>
<ce:source-text>Zhao, J., Brault, J.J., Schild, A., et al.: FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. (2007). https://doi.org/10.1016/j.cmet.2007.11.004</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
</author>
<author seq="2">
<ce:initials>J.G.</ce:initials>
<ce:surname>Jespersen</ce:surname>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J. Biol. Chem</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19460</first-page>
<last-page>19471</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M110.113092</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ref-fulltext>
<ce:source-text>Brault, J.J., Jespersen, J.G., Goldberg, A.L.: Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 285, 19460–19471 (2010). https://doi.org/10.1074/jbc.M110.113092</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Sandri</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Handschin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.0607795103</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ref-fulltext>
<ce:source-text>Sandri, M., Lin, J., Handschin, C., et al.: PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA. (2006). https://doi.org/10.1073/pnas.0607795103</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Raffaello</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Milan</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Masiero</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>J. Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>191</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>101</first-page>
<last-page>113</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201001136</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ref-fulltext>
<ce:source-text>Raffaello, A., Milan, G., Masiero, E., et al.: JunB transcription factor maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 191, 101–113 (2010). https://doi.org/10.1083/jcb.201001136</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>J. Biol. Chem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M113.489716</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ref-fulltext>
<ce:source-text>Lee, D., Goldberg, A.L.: SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J. Biol. Chem. (2013). https://doi.org/10.1074/jbc.M113.489716</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>PI3 kinase regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Curr. Top. Microbiol. Immunol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/82-2010-78</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ref-fulltext>
<ce:source-text>Glass, D.J.: PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. (2010). https://doi.org/10.1007/82-2010-78</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Role and regulation of starvation-induced autophagy in the Drosophila fat body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.C.</ce:initials>
<ce:surname>Scott</ce:surname>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Schuldiner</ce:surname>
</author>
<author seq="3">
<ce:initials>T.P.</ce:initials>
<ce:surname>Neufeld</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2004"/>
<ref-text>Dev. Cell</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.devcel.2004.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ref-fulltext>
<ce:source-text>Scott, R.C., Schuldiner, O., Neufeld, T.P.: Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell. (2004). https://doi.org/10.1016/j.devcel.2004.07.009</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
</author>
<author seq="2">
<ce:initials>A.R.</ce:initials>
<ce:surname>Amini</ce:surname>
</author>
<author seq="3">
<ce:initials>A.A.</ce:initials>
<ce:surname>Amini</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>J. Biol. Chem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M407517200</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ref-fulltext>
<ce:source-text>Latres, E., Amini, A.R., Amini, A.A., et al.: Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J. Biol. Chem. (2005). https://doi.org/10.1074/jbc.M407517200</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Shimizu</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Yoshikawa</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Ito</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Cell Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cmet.2011.01.001</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ref-fulltext>
<ce:source-text>Shimizu, N., Yoshikawa, N., Ito, N., et al.: Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. (2011). https://doi.org/10.1016/j.cmet.2011.01.001</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>Endocrinology</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1210/en.2006-0251</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ref-fulltext>
<ce:source-text>Wang, X., Hu, Z., Hu, J., et al.: Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. (2006). https://doi.org/10.1210/en.2006-0251</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Watts</ce:surname>
</author>
<author seq="2">
<ce:initials>A.J.</ce:initials>
<ce:surname>McAinch</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Obesity</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/oby.20070</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ref-fulltext>
<ce:source-text>Watts, R., McAinch, A.J., Dixon, J.B., et al.: Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity. (2013). https://doi.org/10.1002/oby.20070</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Devivo</ce:surname>
</author>
<author seq="3">
<ce:initials>D.H.R.</ce:initials>
<ce:surname>Hoyle</ce:surname>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1995"/>
<ref-text>Am. J. Physiol. Endocrinol. Metab</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ref-fulltext>
<ce:source-text>Baracos, V.E., DeVivo, C., Hoyle, D.H.R., Goldberg, A.L.: Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am. J. Physiol. Endocrinol. Metab. (1995). https://doi.org/10.1152/ajpendo.1995.268.5.e996</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexi</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Wyke</ce:surname>
</author>
<author seq="3">
<ce:initials>S.T.</ce:initials>
<ce:surname>Russell</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Br. J. Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/sj.bjc.6602780</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Wyke, S.M., Russell, S.T., et al.: Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br. J. Cancer. (2005b). https://doi.org/10.1038/sj.bjc.6602780</ref-fulltext>
<ce:source-text>Khal, J., Wyke, S.M., Russell, S.T., et al.: Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia. Br. J. Cancer. (2005b). https://doi.org/10.1038/sj.bjc.6602780</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Ballarò</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Martinez-Cristobal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J. Mol. Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.jmb.2019.05.032</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ref-fulltext>
<ce:source-text>Penna, F., Ballarò, R., Martinez-Cristobal, P., et al.: Autophagy exacerbates muscle wasting in cancer cachexia and impairs mitochondrial function. J. Mol. Biol. (2019). https://doi.org/10.1016/j.jmb.2019.05.032</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Oncol. Rep</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.2015.3845</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ref-fulltext>
<ce:source-text>Yuan, L., Han, J., Meng, Q., et al.: Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncol. Rep. (2015). https://doi.org/10.3892/or.2015.3845</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of ubiquitin ligases required for skeletal Muscle Atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.C.</ce:initials>
<ce:surname>Bodine</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Latres</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Baumhueter</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2001"/>
<ref-text>Science</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1126/science.1065874</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ref-fulltext>
<ce:source-text>Bodine, S.C., Latres, E., Baumhueter, S., et al.: Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science. (2001). https://doi.org/10.1126/science.1065874</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in disease: Molecular mechanisms and promising therapies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="2">
<ce:initials>J.A.</ce:initials>
<ce:surname>Nathan</ce:surname>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>Nat. Rev. Drug Discov</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>58</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrd4467</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ref-fulltext>
<ce:source-text>Cohen, S., Nathan, J.A., Goldberg, A.L.: Muscle wasting in disease: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015). https://doi.org/10.1038/nrd4467</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
</author>
<author seq="2">
<ce:initials>S.K.R.</ce:initials>
<ce:surname>Mukkamalla</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Calderon</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Br. J. Med. Pract</ref-text>
</ref-info>
<ref-fulltext>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ref-fulltext>
<ce:source-text>Chakraborty, R., Mukkamalla, S.K.R., Calderon, N.: Bortezomib induced reversible left ventricular systolic dysfunction: A case report and review of literature. Br. J. Med. Pract. (2013)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.W.</ce:initials>
<ce:surname>Grandin</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Ky</ce:surname>
</author>
<author seq="3">
<ce:initials>R.F.</ce:initials>
<ce:surname>Cornell</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2015"/>
<ref-text>J. Card. Fail</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cardfail.2014.11.008</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ref-fulltext>
<ce:source-text>Grandin, E.W., Ky, B., Cornell, R.F., et al.: Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J. Card. Fail. (2015). https://doi.org/10.1016/j.cardfail.2014.11.008</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hacihanefioglu</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Tarkun</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Gonullu</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Int. J. Hematol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s12185-008-0139-7</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ref-fulltext>
<ce:source-text>Hacihanefioglu, A., Tarkun, P., Gonullu, E.: Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int. J. Hematol. (2008). https://doi.org/10.1007/s12185-008-0139-7</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Primary proteasome inhibition results in cardiac dysfunction. </ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Herrmann</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Wohlert</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Saguner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Eur. J. Heart Fail</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/eurjhf/hft034</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ref-fulltext>
<ce:source-text>Herrmann, J., Wohlert, C., Saguner, A.M., et al.: Primary proteasome inhibition results in cardiac dysfunction. Eur. J. Heart Fail. (2013). https://doi.org/10.1093/eurjhf/hft034</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Jorge</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Patricia</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Asaf</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Circulation</ref-text>
</ref-info>
<ref-fulltext>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ref-fulltext>
<ce:source-text>Jorge, R., Patricia, C., Asaf, R., et al.: Left ventricular dysfunction development after bortezomib treatment in patients with oncologic diagnoses. Circulation. (2013)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-title>
<ref-titletext-english>Bortezomib-induced severe congestive heart failure</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Jerkins</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2010"/>
<ref-text>Cardiol. Res</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.4021/cr105e</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ref-fulltext>
<ce:source-text>Jerkins, J.: Bortezomib-induced severe congestive heart failure. Cardiol. Res. (2010). https://doi.org/10.4021/cr105e</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Unexpected cardiotoxicity in haematological bortezomib treated patients [1]</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Orciuolo</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Gabriele</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Cecconi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Br. J. Haematol</ref-text>
</ref-info>
<ref-fulltext>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ref-fulltext>
<ce:source-text>Orciuolo, E., Gabriele, B., Cecconi, N., et al.: Unexpected cardiotoxicity in haematological bortezomib treated patients [1]. Br. J. Haematol. (2007)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Takakuwa</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Otomaru</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Araki</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>Case Reports Hematol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1155/2019/1816287</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ref-fulltext>
<ce:source-text>Takakuwa, T., Otomaru, I., Araki, T., et al.: The first autopsy case of fatal acute cardiac failure after administration of carfilzomib in a patient with multiple myeloma. Case Reports Hematol. (2019). https://doi.org/10.1155/2019/1816287</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Voortman</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Giaccone</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2006"/>
<ref-text>BMC Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1471-2407-6-129</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ref-fulltext>
<ce:source-text>Voortman, J., Giaccone, G.: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: A case report. BMC Cancer. (2006). https://doi.org/10.1186/1471-2407-6-129</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Bonetto</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12050</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ref-fulltext>
<ce:source-text>Penna, F., Bonetto, A., Aversa, Z., et al.: Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia. Sarcopenia Muscle. (2016). https://doi.org/10.1002/jcsm.12050</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kou</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>J. Cancer Res. Clin. Oncol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1007/s00432-013-1412-6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ref-fulltext>
<ce:source-text>Zhang, L., Tang, H., Kou, Y., et al.: MG132-mediated inhibition of the ubiquitin-proteasome pathway ameliorates cancer cachexia. J. Cancer Res. Clin. Oncol. (2013b). https://doi.org/10.1007/s00432-013-1412-6</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Bowen</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Adams</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Werner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12233</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ref-fulltext>
<ce:source-text>Bowen, T.S., Adams, V., Werner, S., et al.: Small-molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia. J. Cachexia. Sarcopenia Muscle. (2017). https://doi.org/10.1002/jcsm.12233</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Cong</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Tien</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>Hum. Gene Ther</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1089/hum.2010.057</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ref-fulltext>
<ce:source-text>Cong, H., Sun, L., Liu, C., Tien, P.: Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Hum. Gene Ther. (2011). https://doi.org/10.1089/hum.2010.057</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wada</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kato</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Okutsu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>J. Biol. Chem</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1074/jbc.M111.271270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ref-fulltext>
<ce:source-text>Wada, S., Kato, Y., Okutsu, M., et al.: Translational suppression of atrophic regulators by Micro RNA-23a integrates resistance to skeletal muscle atrophy. J. Biol. Chem. (2011). https://doi.org/10.1074/jbc.M111.271270</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Klaude</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Fredriksson</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:surname>Tjäder</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2007"/>
<ref-text>Clin. Sci</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20060265</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ref-fulltext>
<ce:source-text>Klaude, M., Fredriksson, K., Tjäder, I., et al.: Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. (2007). https://doi.org/10.1042/CS20060265</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Tiao</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Hobler</ce:surname>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1997"/>
<ref-text>J. Clin. Investig</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1172/JCI119143</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ref-fulltext>
<ce:source-text>Tiao, G., Hobler, S., Wang, J.J., et al.: Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J. Clin. Investig. (1997). https://doi.org/10.1172/JCI119143</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Llovera</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Garcia-Martinez</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Agell</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="1998"/>
<ref-text>Int. J. Mol. Med</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/ijmm.2.1.69</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ref-fulltext>
<ce:source-text>Llovera, M., Garcia-Martinez, C., Agell, N., et al.: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int. J. Mol. Med. (1998). https://doi.org/10.3892/ijmm.2.1.69</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Al-Khalili</ce:surname>
</author>
<author seq="2">
<ce:initials>B.T.</ce:initials>
<ce:surname>de Castro</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Östling</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2014"/>
<ref-text>Am. J. Physiol. Cell Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpcell.00110.2014</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ref-fulltext>
<ce:source-text>Al-Khalili, L., de Castro, B.T., Östling, J., et al.: Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am. J. Physiol. Cell Physiol. (2014). https://doi.org/10.1152/ajpcell.00110.2014</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Suetta</ce:surname>
</author>
<author seq="2">
<ce:initials>U.</ce:initials>
<ce:surname>Frandsen</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Jensen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Plos One</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1371/journal.pone.0051238</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ref-fulltext>
<ce:source-text>Suetta, C., Frandsen, U., Jensen, L., et al.: Aging affects the transcriptional regulation of human skeletal muscle disuse atrophy. PLoS One. (2012). https://doi.org/10.1371/journal.pone.0051238</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.T.</ce:initials>
<ce:surname>Langer</ce:surname>
</author>
<author seq="2">
<ce:initials>J.M.G.</ce:initials>
<ce:surname>Senden</ce:surname>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Gijsen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>Front. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3389/fphys.2018.01220</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ref-fulltext>
<ce:source-text>Langer, H.T., Senden, J.M.G., Gijsen, A.P., et al.: Muscle atrophy due to nerve damage is accompanied by elevated myofibrillar protein synthesis rates. Front. Physiol. (2018). https://doi.org/10.3389/fphys.2018.01220</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle proteasome activity correlates with disease severity in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2003"/>
<ref-text>Ann. Surg</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann. Surg. (2003). https://doi.org/10.1097/01.SLA.0000055225.96357.71</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Increased muscle ubiquitin mrna levels in gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Bossola</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Muscaritoli</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Costelli</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2001"/>
<ref-text>Am. J. Physiol. Regul. Integr. Comp. Physiol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ref-fulltext>
<ce:source-text>Bossola, M., Muscaritoli, M., Costelli, P., et al.: Increased muscle ubiquitin mrna levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2001). https://doi.org/10.1152/ajpregu.2001.280.5.r1518</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.H.C.</ce:initials>
<ce:surname>Dejong</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Busquets</ce:surname>
</author>
<author seq="3">
<ce:initials>A.G.W.</ce:initials>
<ce:surname>Moses</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Oncol. Rep</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3892/or.14.1.257</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ref-fulltext>
<ce:source-text>Dejong, C.H.C., Busquets, S., Moses, A.G.W., et al.: Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia. Oncol. Rep. (2005). https://doi.org/10.3892/or.14.1.257</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Khal</ce:surname>
</author>
<author seq="2">
<ce:initials>A.V.</ce:initials>
<ce:surname>Hine</ce:surname>
</author>
<author seq="3">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2005"/>
<ref-text>Int. J. Biochem. Cell Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.biocel.2004.10.017</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ref-fulltext>
<ce:source-text>Khal, J., Hine, A.V., Fearon, K.C.H., et al.: Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int. J. Biochem. Cell Biol. (2005a). https://doi.org/10.1016/j.biocel.2004.10.017</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.S.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Ye</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.Y.</ce:initials>
<ce:surname>Qian</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>J. Exp. Clin. Can</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1186/1756-9966-31-81</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ref-fulltext>
<ce:source-text>Sun, Y.S., Ye, Z.Y., Qian, Z.Y., et al.: Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. J. Exp. Clin. Cancer Res. (2012). https://doi.org/10.1186/1756-9966-31-81</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Williams</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="3">
<ce:initials>J.E.</ce:initials>
<ce:surname>Fischer</ce:surname>
</author>
<author seq="4">
<ce:initials>P.O.</ce:initials>
<ce:surname>Hasselgren</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="1999"/>
<ref-text>Surgery</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/S0039-6060(99)70131-5</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ref-fulltext>
<ce:source-text>Williams, A., Sun, X., Fischer, J.E., Hasselgren, P.O.: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. (1999). https://doi.org/10.1016/S0039-6060(99)70131-5</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Aniort</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Stella</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Philipponnet</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2019"/>
<ref-text>J. Cachexia. Sarcopenia Muscle</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1002/jcsm.12376</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ref-fulltext>
<ce:source-text>Aniort, J., Stella, A., Philipponnet, C., et al.: Muscle wasting in patients with end-stage renal disease or early-stage lung cancer: Common mechanisms at work. J. Cachexia. Sarcopenia Muscle. (2019). https://doi.org/10.1002/jcsm.12376</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.T.</ce:initials>
<ce:surname>Jagoe</ce:surname>
</author>
<author seq="2">
<ce:initials>C.P.F.</ce:initials>
<ce:surname>Redfern</ce:surname>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Roberts</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>Clin. Sci</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1042/CS20010270</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ref-fulltext>
<ce:source-text>Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., et al.: Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clin. Sci. (2002). https://doi.org/10.1042/CS20010270</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-cachexia in patients with stages I-III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Op Den Kamp</ce:surname>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>Langen</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Minnaard</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>Lung Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.lungcan.2011.09.012</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ref-fulltext>
<ce:source-text>Op den Kamp, C.M., Langen, R.C., Minnaard, R., et al.: Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer. (2012). https://doi.org/10.1016/j.lungcan.2011.09.012</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Murton</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Maddocks</ce:surname>
</author>
<author seq="3">
<ce:initials>F.B.</ce:initials>
<ce:surname>Stephens</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Clin. Lung Cancer</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cllc.2016.06.003</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ref-fulltext>
<ce:source-text>Murton, A.J., Maddocks, M., Stephens, F.B., et al.: Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. Clin. Lung Cancer. (2017). https://doi.org/10.1016/j.cllc.2016.06.003</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Okamoto</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Torii</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Machida</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2011"/>
<ref-text>J. Physiol. Sci</ref-text>
</ref-info>
<ref-fulltext>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ref-fulltext>
<ce:source-text>Okamoto, T., Torii, S., Machida, S.: Differential gene expression of muscle-specific ubiquitin ligase MAFbx/Atrogin-1 and MuRF1 in response to immobilization-induced atrophy of slow-twitch and fast-twitch muscles. J. Physiol. Sci. (2011)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Breakdown of filamentous myofibrils by the UPS-step by step</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2021"/>
<ref-text>Biomol. Ther</ref-text>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3390/biom11010110</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ref-fulltext>
<ce:source-text>Aweida, D., Cohen, S.: Breakdown of filamentous myofibrils by the UPS-step by step. Biomol. Ther. 11 (2021). https://doi.org/10.3390/biom11010110</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Aweida</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Rudesky</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<ref-text>J. Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>217</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3698</first-page>
<last-page>3714</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201802018</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ref-fulltext>
<ce:source-text>Aweida, D., Rudesky, I., Volodin, A., et al.: GSK3-β promotes calpain-1-mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 217, 3698–3714 (2018). https://doi.org/10.1083/jcb.201802018</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="2">
<ce:initials>J.J.</ce:initials>
<ce:surname>Brault</ce:surname>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2009"/>
<ref-text>Cell Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.200901052</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ref-fulltext>
<ce:source-text>Cohen, S., Brault, J.J., Gygi, S.P., et al.: During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. (2009). https://doi.org/10.1083/jcb.200901052</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Zhai</ce:surname>
</author>
<author seq="3">
<ce:initials>S.P.</ce:initials>
<ce:surname>Gygi</ce:surname>
</author>
<author seq="4">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2012"/>
<ref-text>J. Cell Biol</ref-text>
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>575</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1083/jcb.201110067</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ref-fulltext>
<ce:source-text>Cohen, S., Zhai, B., Gygi, S.P., Goldberg, A.L.: Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments in muscle atrophy. J. Cell Biol. 198, 575–589 (2012). https://doi.org/10.1083/jcb.201110067</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Volodin</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Kosti</ce:surname>
</author>
<author seq="3">
<ce:initials>A.L.</ce:initials>
<ce:surname>Goldberg</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Cohen</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Proc. Natl. Acad. Sci. USA</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1073/pnas.1612988114</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ref-fulltext>
<ce:source-text>Volodin, A., Kosti, I., Goldberg, A.L., Cohen, S.: Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA. (2017). https://doi.org/10.1073/pnas.1612988114</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagic degradation contributes to muscle wasting in cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Penna</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Costamagna</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2013"/>
<ref-text>Am. J. Pathol.</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ajpath.2012.12.023</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ref-fulltext>
<ce:source-text>Penna, F., Costamagna, D., Pin, F., et al.: Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. (2013). https://doi.org/10.1016/j.ajpath.2012.12.023</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Autophagy is induced in the skeletal muscle of cachectic cancer patients.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Aversa</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Pin</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lucia</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2016"/>
<ref-text>Sci. Rep.</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/srep30340</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ref-fulltext>
<ce:source-text>Aversa, Z., Pin, F., Lucia, S., et al.: Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. (2016). https://doi.org/10.1038/srep30340</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pettersen</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Andersen</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Degen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2017"/>
<ref-text>Sci. Rep</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/s41598-017-02088-2</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ref-fulltext>
<ce:source-text>Pettersen, K., Andersen, S., Degen, S., et al.: Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling. Sci. Rep. (2017). https://doi.org/10.1038/s41598-017-02088-2</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Striated muscle cytoarchitecture: An intricate web of form and function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.A.</ce:initials>
<ce:surname>Clark</ce:surname>
</author>
<author seq="2">
<ce:initials>A.S.</ce:initials>
<ce:surname>McElhinny</ce:surname>
</author>
<author seq="3">
<ce:initials>M.C.</ce:initials>
<ce:surname>Beckerle</ce:surname>
</author>
<author seq="4">
<ce:initials>C.C.</ce:initials>
<ce:surname>Gregorio</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2002"/>
<ref-text>Annu. Rev. Cell Dev. Biol</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ref-fulltext>
<ce:source-text>Clark, K.A., McElhinny, A.S., Beckerle, M.C., Gregorio, C.C.: Striated muscle cytoarchitecture: An intricate web of form and function. Annu. Rev. Cell Dev. Biol. (2002). https://doi.org/10.1146/annurev.cellbio.18.012502.105840</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Dahme</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2008"/>
<ref-text>Cardiovasc. Res</ref-text>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1093/cvr/cvn073</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ref-fulltext>
<ce:source-text>Chen, Z., Huang, W., Dahme, T., et al.: Depletion of zebrafish essential and regulatory myosin light chains reduces cardiac function through distinct mechanisms. Cardiovasc. Res. (2008). https://doi.org/10.1093/cvr/cvn073</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>


</unit-content>
</unit>
</units>